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2Abstract
1. This work studied the smooth muscle of the rabbit ductus arteriosus. The 
ductus is a shunt blood vessel of the fetus which extends between the 
main pulmonary artery and aorta and closes after birth.
2. This work had the following aims regarding the isolated fetal rabbit 
ductus arteriosus (a) to characterise the ideal experimental conditions for 
study of the vessel; (b) to characterise the dilator prostanoid receptors on 
the vessel; (c) to characterise the effect of prostaglandin E2  (PGE2) on the 
response of the vessel to noradrenaline; (d) to characterise the effect of 
indomethacin on the response of the vessel to PGE2  and other 
vasodilators; (e) to characterise the effect of oxygen tension on both the 
response of the vessel to the contractile effect of noradrenaline and the 
relaxant effect of PGE2  and other vasodilators; and, (f) to characterise 
contractile effects of prostanoids on the vessel.
3. The ductus arteriosus was isolated from fetal New Zealand White rabbits 
obtained at 28 days gestation following Caesarean section of the 
sacrificed mother. The vessel was mounted in vitro as a ring preparation 
and its responses to contractile and relaxant agonists were quantified. The 
effects of experimental manipulations on these responses were studied, 
namely, the effects of receptor antagonists, enzyme inhibitors and varying 
oxygen tension.
4. The ideal experimental conditions for the study of contractile and 
relaxant responses were characterised looking at the effects of 
noradrenaline and PGE2.
5. The dilator prostanoid receptors (P receptors, e.g. PGE2  receptor = EP 
receptor) on the ductus were characterised with the vessel pre-contracted
3with ljiM indomethacin and 25mM K+ in 15% oxygen. Of a range of 
synthetic prostanoids with selective agonism at EPj, EP2  or EP3  receptors, 
all were at least 1 0 0  times less potent than PGE2  (EC50 [i.e. interpolated 
molar concentration causing 50% maximum response] = 0.36nM). The 
rank order of potency was: PGE2  »  misoprostol (145-fold less potent) > 
GR63799X (685-fold less potent) »  AH13205 (>100,000-fold less 
potent) > sulprostone (>10,000-fold less potent) > 0. The EPj antagonists, 
AH6809 (10|iM) and SC19220 (30pM), had no significant effect on the 
sensitivity of the ductus to PGE2. The EP4  antagonist, AH23848B, caused 
concentration-related shifts to the right of the PGE2  concentration 
relaxation response curve yielding a pA2  of 4.91 but with a Schild plot 
slope of 1.46. The EP2  agonist, AH13205, while only causing a very small 
relaxation, acted as a competitive antagonist of PGE2  with a pA2  of 4.85. 
Cicaprost (selective IP agonist) and BW245C (selective DP agonist) both 
relaxed the ductus but were less potent than PGE2  (110-fold less potent 
and 875-fold less potent, respectively). AH23848B and AH13205 (both 
30pM) inhibited the sensitivity of the ductus to BW245C to a similar 
extent as that to PGE2  but had little or no effect on its sensitivity to 
cicaprost. The selective DP receptor blocking drug, BW8 6 8 C (10|iM), 
caused no significant decrease in sensitivity to BW245C.
6 . In the absence of indomethacin, PGE2  (from InM to lOOnM) increased 
the EC5 0  to noradrenaline 3 fold. In the presence of lpM  indomethacin, 
PGE2  (0.0InM to lOOnM) increased the EC5 0  to noradrenaline 245 fold. 
By comparing the control pEC5 0  (i.e. -log1 0 EC50) to noradrenaline with 
the relationship between the pEC5 0  to noradrenaline and [PGE2] in l|iM  
indomethacin, the effect of endogenous PGE2  synthesised in the vessel 
wall was estimated as being equivalent to a bath concentration of 
approximately InM exogenous PGE2.
7. When the vessel was pre-contracted with 10pM noradrenaline, 
indomethacin had no effect on the dilator response to PGE2, but did alter
4the response to other vasodilators. The sensitivity of the vessel to 
cicaprost, cromakalim and forskolin was decreased in lpM indomethacin 
compared with control. Forskolin caused complete relaxation in the 
presence and absence of indomethacin. Indomethacin decreased the 
maximum response to cromakalim but increased the maximum response to 
cicaprost. 0.3nM PGE2  partially reversed the effect of indomethacin on the 
sensitivity of the vessel to forskolin.
8 . Oxygen tension had no effect on the maximum contractile response 
(MCR) to noradrenaline in 0.01 nM PGE2, but a profound inhibitory effect 
of fetal oxygen tension on the MCR to noradrenaline was uncovered by 
PGE2  in a concentration-dependent manner across the range 0.1-10nM.
9. With the ductus pre-contracted with lpM  indomethacin and 10|iM 
noradrenaline, nifedipine and atrial natriuretic peptide had no effect on 
ductal tone in either 2% or 15% oxygen (oxygen tension: 19-23mmHg and 
100-1 lOmmHg, respectively). In 15% oxygen, the rank order of maximum 
relaxant response (MRR) to dilator agonists was forskolin > cicaprost > 
PGE2  »  cromakalim »  sodium nitroprusside * adenosine » 0. The MRR 
of all agonists was increased in 2 % oxygen except forskolin which caused 
complete relaxation in 15% oxygen. In 15% oxygen, the rank order of 
pEC5 0  was PGE2  »  cicaprost ~ cromakalim ~ forskolin. PGE2  was about 
70 times more potent than cicaprost. The pEC5 0  of all four agonists was 
increased in 2% oxygen. The increase in pEC5 0  could not be explained by 
a decreased extent of pre-contraction. The MRR to PGE2  in 15% oxygen 
and the magnitude of the increase in pEC5 0  to PGE2  going from 15% to 
2% oxygen were the same in lpM flubriprofen, lpM indomethacin or in 
the absence of these drugs. However, in 2% oxygen, the MRR to PGE2  
was increased in lpM  indomethacin or lpM flubriprofen compared with 
control.
10. In lpM indomethacin and 300nM forskolin, both U46619 (TP agonist) 
and sulprostone (EPj and EP3  agonist) caused concentration-dependent
5contractions of the ductus in the nanomolar range (EC50s 33nM and 
42nM, respectively). The response to U46619 was shifted to the right by 
the TP receptor antagonist EP 092. Responses to GR63799X (EPJ and 
EP3  agonist) and PGF2a were complicated by the fact that these agonists 
caused relaxation at high concentrations (>30nM). In lOnM PGE2, 
U46619, sulprostone and GR63799X elicited similar contractile responses, 
whereas PGF2a had no effect. Incubation in lOnM U46619 or PGF2ot had 
no effect on the sensitivity of the ductus to the dilator effect of PGE2. 
However, lOnM sulprostone increased the EC5 0  to PGE2  by 119% and 
3|xM sulprostone increased it by 157%.
11. The main conclusions drawn from this work are as follows:
(a) the dilator EP receptor on the ductus arteriosus is not EPj, EP2, or EP3, 
but probably the recently described EP4  sub-type
(b) the ductus arteriosus has a dilator IP receptor, but no DP receptor
(c) PGE2  inhibits the sensitivity of the ductus arteriosus to noradrenaline
(d) indomethacin alters the response of the ductus to exogenous dilators 
by the elimination of endogenous PGE2  and PGI2
(e) fetal oxygen tension and PGE2  act synergistically to inhibit the 
response of the ductus to noradrenaline
(e) raising the oxygen tension in the physiological range which occurs at 
birth decreases the sensitivity of the ductus to a diverse range of 
vasodilators
(f) an endogenous cyclo-oxygenase product inhibits the response of the 
ductus to PGE2  in fetal oxygen tension
(g) the ductus has a contractile TP receptor and a contractile EP receptor 
(probably EP3) and the latter inhibits the vessel's sensitivity to the dilator 
effect of PGE2.
(h) pooling the findings with cicaprost (in 5, 7 and 9 above), PGI2  almost 
certainly has a physiological role in the control of ductus arteriosus smooth 
muscle.
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Chapter 1. Introduction.
1.1 The physiology of the ductus arteriosus.
1.1.1 The ductus arteriosus: an overview.
The ductus arteriosus is a fetal shunt blood vessel which extends between 
the main pulmonary artery and the descending aorta. It is patent in fetal 
and early neonatal life. The direction of flow is determined by the pressure 
gradient across the vessel, which is a function, therefore, of the aortic and 
pulmonary artery pressures. In the fetus, blood flow is from the pulmonary 
artery to the aorta but the direction of blood flow across the ductus 
reverses soon after birth. The vessel closes in the first few days of life. In 
fetal life, the function of the ductus is to divert deoxygenated blood from 
the pulmonary circulation to the descending aorta where a proportion is 
diverted to the umbilico-placental circulation, where gaseous exchange 
takes place. Patency of the ductus in early neonatal life improves 
pulmonary blood flow and arterial oxygen tension and is one of the 
features of the transitional circulation of the neonate.
Contraction of ductus arteriosus smooth muscle is inhibited in utero by 
prostaglandins. At birth, elimination of this inhibitory effect and the direct 
contractile effect of increasing oxygen tension and of humoral 
vasoconstrictors cause contraction of the ductus resulting in its closure, 
typically within 48 hours of birth (in the human). The lumen is then 
obliterated by necrosis. The ability to manipulate ductal patency by 
controlling ductal smooth muscle is important in a number of clinical 
situations. This thesis concentrates on the control of contractility of ductus 
arteriosus smooth muscle.
1.1.2 The fetal circulation.
One of the fundamental differences between the fetal and adult
19
circulations is that in the fetus the two ventricles of the heart pump in 
parallel due to the presence of shunts, whereas in the adult the ventricles 
pump in series. There are three main shunts in the fetal circulation: the 
ductus arteriosus, the ductus venosus and the foramen ovale (see Mott, 
1982 for review). In the fetus, the ductus arteriosus shunts blood from the 
pulmonary artery to the descending aorta. Right ventricular output in the 
fetus is 65% of the combined ventricular output1 (CVO) and, as in the 
adult, this is deoxygenated blood. Clearly, the lungs are not ventilated in 
utero, and gaseous exchange takes place at the placenta. There is a need, 
therefore, for the redirecting of this deoxygenated blood to the umbilico- 
placental circulation. The vast majority of the right ventricular output is 
diverted from the main pulmonary artery, through the ductus (57% CVO), 
to the descending aorta, where a proportion (40% CVO) is diverted to the 
umbilico-placental circulation, where gaseous exchange takes place. There 
is no left to right shunt across the ductus under normal conditions in the 
fetus (Teitel et al, 1987).
The direction of blood flow across the ductus is determined by the 
pressure gradient across the vessel. In the fetus, pulmonary vascular 
resistance is very high due to hypoxic pulmonary vasoconstriction and 
systemic pressure is low due to the presence of the low resistance 
umbilico-placental circulation: the shunt across the ductus is, therefore, 
right to left (Anderson et al, 1981). The current understanding of the 
ductus in the fetus is that it is a relatively passive structure and its role is 
simply to remain widely patent.
1.1.3 The neonatal transitional circulation.
Following birth, the pressure gradient across the ductus is reversed, which 
is mediated by ventilation of the lungs, oxygenation of the lungs and the 
loss of the low resistance umbilico-placental circulation (Teitel et al,
JAs the ventricles pump in parallel, cardiac output in the fetus is expressed as the 
combined ventricular output. In the adult the output of both ventricles is, necessarily, 
the same, and the cardiac output refers to that of each ventricle.
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1987). In the neonate, flow across the ductus is from the aorta to the 
pulmonary artery, until the vessel closes in the first 24 to 48 hours of life 
(Drayton and Skidmore, 1987). Immediately following birth, lung function 
is sub-optimal and arterial oxygen tension is less than in the healthy adult 
(Heymann and Rudolph, 1975). Redirection of blood from the aorta to the 
pulmonary artery through the ductus arteriosus improves arterial oxygen 
tension at the expense of systemic (but not cardiac or cerebral) blood flow 
(Clyman et al, 1987). Ligation of the ductus in the neonatal lamb 
decreases pulmonary blood flow and arterial oxygen tension (Dawes et 
al, 1955). Physiological patency of the ductus in the first hours of life is, 
therefore, an adaptive mechanism which improves arterial oxygen tension 
at a time of critical changes in cardio-respiratory function.
The left to right shunt in the ductus in the human begins to decline a few 
hours after birth and falls steadily until closure (Drayton and Skidmore,
1987). Closure of the ductus is effected by contraction of its thick 
muscular wall. Following this functional closure, fibrosis occurs and 
ultimately a remnant of the vessel is formed, the ligamentum arteriosum. 
The major focus for research on the ductus arteriosus has been the factors 
which control contraction of its smooth muscle. This is the primary interest 
of this thesis and the current state of understanding is reviewed below.
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1.2 Control of ductus arteriosus smooth muscle.
1.2.1 Oxygen.
In fetal life, the ductus is exposed to an oxygen tension of about 20- 
28mmHg and this rises rapidly following birth (see Heymann and Rudolph, 
1975). It was first observed over 50 years ago that the ductus arteriosus 
contracts to increasing oxygen tension (Kennedy and Clark, 1942) and 
this has been postulated to be important in the post-natal closure of the 
vessel. The oxygen contraction of the ductus increases towards term (Noel 
and Cassin, 1976; Clyman et al, 1979) and can be enhanced, in the pre­
term animal, by antenatal administration of hydrocortisone (Clyman et al, 
1981c).
There has been a great deal of work directed at elucidating the mechanism 
of the contractile effect of oxygen. Given the importance of prostaglandins 
in dilating the vessel in utero (see section 1.2.3), a number of authors 
have speculated that the effect of oxygen might be mediated by a 
constrictor metabolite of arachidonic acid.
It has been suggested that PGF2a might mediate the oxygen-induced 
contraction of the ductus (Starling and Eliott, 1974), however, this is 
unlikely as the response to oxygen persists in the presence of the 
prostaglandin synthesis inhibitor, indomethacin (Smith and McGrath,
1988). Likewise, lipoxygenase inhibition has no effect on the oxygen 
contraction (Coceani et al, 1982).
Carbon monoxide relaxes the ductus (Coceani et al, 1984) which led 
these authors to hypothesise that a mono-oxygenase cytochrome P4 5 0  
arachidonic acid metabolite may mediate oxygen contraction of the 
ductus. This hypothesis was supported by two observations: firstly, that 
monochromatic light reversed the effect of carbon monoxide, an effect 
which was maximal at a wavelength of 450nM (characteristic of the P4 5 0
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system) (Coceani et al, 1988); and, secondly, that metyrapone, a chemical 
inhibitor of some cytochrome P4 5 0  isoenzymes, also relaxed the ductus 
(Coceani et al, 1984). However, the same study demonstrated that a 
range of other chemical inhibitors of this system had only minor effects on 
the ductus, which undermined the hypothesis. Furthermore, in the 
presence of combined cyclo-oxygenase and lipoxygenase inhibition, 
arachidonic acid had only a dilator effect on the ductus (Coceani et al,
1988) which suggests that if a chemical mediator of the oxygen-induced 
contraction exists, it is not an arachidonic acid metabolite. The fact that 
carbon monoxide also relaxed the ductus in fetal oxygen tension implies 
that it may relax the ductus by a mechanism unrelated to the oxygen- 
induced contraction. It has been demonstrated that carbon monoxide 
stimulates the synthesis of cyclic guanosine monophosphate (cGMP) and 
relaxes smooth muscle: this is reversed by monochromatic light with a 
maximum effect at 422nM (Utz and Ullrich, 1991). While Coceani found 
that maximal reversal of the effect of carbon monoxide on the ductus 
occurred at 450nM, other authors have found maximal reversal of the 
effect of carbon monoxide on the oxygen-contracted ductus to occur at 
420-425nM (Fay and Jobsis, 1972). Furthermore, a diverse range of 
arachidonic acid epoxides has no contractile effect on the ductus 
(Coceani et al, 1988). It seems unlikely, therefore, that the oxygen- 
induced contraction of the ductus is mediated by a constrictor metabolite 
of arachidonic acid.
Recently, the same group have proposed that endothelin may mediate the 
oxygen-induced contraction of the ductus: endothelin contracts the 
isolated lamb ductus (Coceani et al, 1989); it is released both by the 
endothelium and media of the vessel (Coceani and Kelsey, 1991); the 
release of endothelin is stimulated by increasing oxygen tension (Coceani 
et al, 1992) and the oxygen-induced contraction of the ductus is 
inhibited by the endothelin receptor antagonist BQ123 (Coceani et al,
1992). However, another study demonstrated that endothelin had no
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effect on the lamb ductus in utero (Chatfield et al, 1991), despite the fact 
that oxygen can contract the ductus in utero (Mentzer et al, 1985). 
Furthermore, another study on human cultured ductal cells demonstrated 
no stimulatory effect of oxygen on endothelin release and that ductal 
smooth muscle cells release only 5-10% of the levels of endothelin released 
by endothelial cells (Day et al, 1994). Finally, the oxygen-induced 
contraction of the ductus is unaffected by removal of the endothelium 
(Cobum et al, 1986). These observations suggest that endothelin does 
not mediate the oxygen-induced contraction of the ductus.
Fay (1971) demonstrated some fundamental properties of the oxygen- 
induced contraction of the guinea-pig ductus: oxygen had an effect across 
the range 0-140mmHg; the effect of oxygen was the same whether the 
luminal or the adventitial side of the ductus was exposed to elevated 
oxygen; and local anaesthetics and tetrodotoxin (inhibitors of nerve- 
mediated effects) had no effect on the response to oxygen. These findings 
suggest that oxygen acts directly on the smooth muscle cells of the ductus. 
In addition, Fay observed that the oxygen-induced contraction could be 
inhibited by a diverse range of inhibitors of oxidative phosphorylation and 
that the degree of contraction correlated with oxygen consumption. 
Neither of these facts was true of the acetyl choline-induced contraction 
of the ductus. Fay postulated that cytochrome a3  was the oxygen sensor. 
This was partly based on the effect of carbon monoxide and its reversal by 
light (Fay and Jobsis, 1972). The effects of these on guanylate cyclase 
complicate this interpretation.
It has been demonstrated that increasing oxygen tension depolarises the 
ductus arteriosus (Roulet and Cobum, 1981). More recently it has been 
shown that the oxygen-induced contraction is dependent on the presence 
of extracellular calcium and that it is inhibited by calcium channel 
antagonists to a similar extent to the potassium-induced contraction 
(Nakanishi et al, 1993). Furthermore, glibenclamide, an inhibitor of 
adenosine triphosphate (ATP)-sensitive potassium channels contracts the
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ductus in fetal but not elevated oxygen tension and cromakalim, an ATP- 
sensitive potassium channel opener, completely reverses the oxygen- 
induced contraction of the ductus (Nakanishi et al, 1993). Taken in 
conjunction with the work of Fay, a model for oxygen-induced 
contraction of the ductus has been proposed: in fetal oxygen tension, 
intracellular levels of ATP are low and ductal smooth muscle is 
hyperpolarised by ATP-sensitive potassium channels being open; when 
oxygen is increased, ATP levels rise, closing the potassium channels 
depolarising the cell membrane and causing contraction (Nakanishi et al,
1993). This model is only part of the explanation for the effects of oxygen, 
however, as oxygen can still cause contraction of the ductus in the 
presence of 126mM extracellular potassium (Roulet and Cobum, 1981) 
and calcium channel antagonists do not fully block the oxygen-induced 
contraction (Nakanishi et al, 1993), i.e. oxygen also has a membrane- 
independent contractile effect on the ductus.
1.2.2 Vasoconstrictors.
The ductus arteriosus of all species studied is innervated by catecholamine 
containing nerves (Boreus et al, 1969; Ikeda, 1970; Ikeda et al, 1972; 
Bodach et al, 1980). The catecholamine content of the ductus is similar to 
peripheral arteries which are known to be under autonomic neural control 
(Ikeda et al, 1972). The vessel contracts both in response to transmural 
stimulation of these nerves (Ikeda et al, 1973a; Bodach et al, 1980) and 
exposure to exogenous noradrenaline (Born et al, 1956; Kovalcik, 1963; 
Aronson et al, 1970; Smith and McGrath, 1988). The effect of transmural 
stimulation increases towards term (Ikeda et al, 1973b) and it is also 
potentiated in raised oxygen tension, as is the response of the vessel to 
exogenous noradrenaline (Ikeda et al, 1973a). The effect of transmural 
stimulation is blocked in part by a  adrenoceptor blockade (Bodach et al, 
1980) and treatment of the pregnant guinea pig with phenoxybenzamine 
(an a  adrenoceptor antagonist) delays closure of the ductus in the 
offspring (Hornblad and Larsson, 1972). The ductus also contracts to
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acetyl choline (Kovalcik, 1963; McMurphy and Boreus, 1971; Ikeda et al, 
1973a), and the vessel is innervated with acetyl choline-containing nerves 
(Silva and Ikeda, 1971). The central control of activity of the pressor 
nerves of the ductus is unknown.
The adventitia of the guinea pig ductus has many mast cells present, which 
can release agents such as histamine and 5-hydroxytryptamine (Fay, 1971), 
both of which contract the isolated ductus (Aronson et al, 1970; 
McMurphy and Boreus, 1971). The factors which control degranulation of 
ductal mast cells are not known. The endothelium and media of the ductus 
synthesise the potent peptide vasoconstrictor, endothelin (Coceani and 
Kelsey, 1991). Endothelin contracts the isolated lamb ductus (Coceani et 
al, 1989) but has no effect on the vessel when infused into the 
chronically instrumented fetal lamb (Chatfield et al, 1991).
The ductus also contracts in response to circulating vasoactive agents, 
notably adrenaline (Kovalcik, 1963), through a  adrenoceptors, and 
bradykinin (Kovalcik, 1963; Aronson et al, 1970). The latter is released 
following ventilation of the lungs with oxygen (Heymann et al, 1969) 
and levels of bradykinin in human cord blood are higher than the adult 
(Melmon et al, 1968). The ductus also contracts in response to steroid 
hormones, namely, glucocorticoids (Momma et al, 1981) and progesterone 
(Pulkkinen et al, 1986). The effects of the former are probably related to 
modulating the sensitivity of the ductus to the dilator effect of 
prostaglandin E2  (PGE2) (see section 1.2.3). The mechanism of action of 
progesterone is unknown but, unlike glucocorticoids (Momma and Takao, 
1989a), it does not interact with the effect of indomethacin (Pulkkinen et 
al, 1986).
The response of the ductus to exogenous vasoconstrictors in utero seems 
to be less than the isolated ductus in vitro (Friedman et al, 1983, and as 
discussed above for endothelin). This may be due to an inhibitory effect of
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prostaglandins, as the response of the ductus to exogenous noradrenaline 
is potentiated by indomethacin (Smith and McGrath, 1988). Furthermore, 
fetal oxygen tension inhibits the response of the isolated ductus to 
transmural stimulation and application of exogenous noradrenaline and 
acetyl choline (Ikeda et al, 1973a).
1.2.3 Prostaglandins.
Prostaglandins are oxygenated derivatives of the 20 carbon chain fatty 
acid, arachidonic acid, formed from the cyclo-oxygenase pathway. They 
generally act as local hormones with diverse biological effects. Each of the 
main naturally occurring prostaglandins acts at its own receptor, named 
after it (e.g. EP for PGE2, IP for PGI2, TP for TxA2, etc.). The EP receptors 
have been divided into sub-types. For reviews of prostanoid 
pharmacology, see Coleman et al, (1990 and 1994b) and Smith et al, 
(1991).
In 1973, Coceani and Olley demonstrated that PGEj and PGE2  relaxed the 
isolated lamb ductus arteriosus. It was then demonstrated that 
indomethacin contracted the vessel both in vivo (Sharpe et al, 1974) and 
in vitro (Coceani et al, 1975). The effect of indomethacin is likely to be 
due to its inhibitory effect on cyclo-oxygenase, as a range of structurally 
diverse cyclo-oxygenase inhibitors contracted the vessel (Momma et al, 
1984). This suggests that the net effect of prostaglandins on the ductus is 
inhibitory. With one exception (see below), all studies (in diverse species) 
have demonstrated that prostaglandins relax the ductus (Coceani et al, 
1975; Sharpe and Larsson, 1975; Starling et al, 1976; Clyman et al, 
1977a, 1978a and 1978c; Coceani et al, 1978b; Coceani et al, 1980; 
Momma et al, 1980; Friedman et al, 1985; Sideris et al, 1985).
The ductus is exposed to both locally released and circulating 
prostaglandins. The isolated ductus synthesises a range of prostaglandins: 
PGI2  is the main product of arachidonic acid in the vessel and, indeed, is 
the only prostaglandin for which there is clear evidence of catalytic
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production (Terragno et al, 1977; Pace-Asciak and Rangaraj, 1977, 1978 
and 1983; Skidgell et al, 1984). The ductus also forms small amounts of 
PGE2, PGF2a and PGD2  (all about 10% the level of PGI2  synthesis). 
Prostaglandins are formed by both endothelial and smooth muscle cells of 
the ductus (Rabinovitch et al, 1989). It is thought that PGE2  is formed by 
degradation of PGH2  and not through an enzymatic pathway (Needleman 
et al, 1981; Skidgell et al, 1984). The ductus does, however, have 
catabolic enzymes for PGE2  (Pace-Asciak and Rangaraj, 1978).
The ductus is also exposed to circulating PGE2  and it has been suggested 
that circulating PGE2  is more important in the the control of the ductus 
than locally released PGE2  (Clyman, 1987). Circulating concentrations of 
PGE2  increase towards term and are approximately l-2nM in the term fetal 
lamb (Clyman et al, 1980c). These fall dramatically at birth, by 10-fold at 1 
hour and by 20-fold at 3 hours (Clyman et al, 1980c). Loss of the dilator 
effect of circulating PGE2  has been postulated to be fundamental to the 
closure of the ductus (Clyman, 1987). The fall in circulating concentrations 
of PGE2  is thought to be due largely to the increase in lung blood flow 
that occurs at birth, as the lungs are the major site of prostaglandin 
catabolism. The main catabolic pathway for PGE2  is 15 (OH) prostaglandin 
dehydrogenase: the activity of this enzyme in the lung and kidney 
increases towards term (Simberg, 1983; Tsai and Einzig, 1989) and activity 
can be induced in the pre-term animal by the administration of 
hydrocortisone (Tsai and Brown, 1987).
The contractile effect of indomethacin is assumed to be due primarily to the 
elimination of PGE2  (Clyman, 1987; Coceani and Olley, 1988) as it is by far 
the most potent prostanoid dilator of the ductus and, specifically, is about 
1 0 0 0  times more potent than the main prostanoid synthesised by the 
vessel, PGI2  (Coceani et al, 1978b, Clyman et al, 1978c). 6 -keto-PGEj is 
almost as potent as PGE2  and could, theoretically, be formed from PGI2, 
however, the enzymes required for this have not been demonstrated in the
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ductus (Coceani et al, 1980).
A dose of lOmg/kg indomethacin to the pregnant rat causes 70% 
constriction of the ductus of its fetuses, and this leads to signs of right 
sided heart failure in 1-8 hours and right ventricular hypertrophy within 24 
hours (Momma and Takao, 1989b). The effect of indomethacin varies with 
gestational age, but the findings are different comparing in vitro and in 
vivo studies. The contractile effect of indomethacin and ibuprofen on the 
isolated ductus decreased towards term (Clyman et al, 1978b; Coceani et 
al, 1979), whereas the contractile effect of indomethacin in vivo was 
either the same comparing term and pre-term, or greater in term animals 
(Friedman et al, 1983; Momma and Takao, 1987; Moise et al, 1988). No 
explanation has been advanced for this discrepancy.
The sensitivity of the ductus to PGE2  and PGI2  decreases towards term 
(Clyman et al, 1980b). The sensitivity of the pre-term lamb to these agents 
can be decreased by antenatal administration of glucocorticoids to the 
mother (Clyman et al, 1981c). Persistent patency of the ductus in the pre­
term neonate is related both to elevated circulating concentrations of PGE2  
and to increased sensitivity of the vessel to its dilator effect (Clyman et al, 
1983b). Antenatal administration of glucocorticoids decreases the 
incidence of persistent patency of the ductus in premature human 
neonates (Clyman et al, 1981b). The pre-term ductus has greater PGI2  
synthase activity than term (Clyman et al, 1978d), but releases less PGE2  
than the term ductus (Clyman et al, 1979). The increased activity of PGI2  
synthase in the pre-term ductus may result in less accumulation of PGH2  
and, since PGE2  is formed by degradation of PGH2, may explain the low 
levels of PGE2  released. Antenatal administration of hydrocortisone has no 
effect on PGE2  release from the isolated pre-term ductus (Clyman et al, 
1981a).
It has been reported in some studies that increasing oxygen tension 
decreases the sensitivity of the ductus to PGE2  (Coceani et al, 1975) but
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other studies have failed to reproduce this finding (Clyman et al, 1977a). 
Where an effect of oxygen was observed, it was abolished by 
indomethacin (Coceani et al, 1975). The two protagonists in this debate 
discussed their different findings in some detail and, essentially, the 
difference remained unexplained (Coceani and Olley, 1977; Clyman et al, 
1977b). It has been suggested that the discrepancy may be due to the 
failure of one group to include C 0 2  in their gas bubbling system (Smith 
and McGrath, 1988), a technical difference overlooked by both groups. 
The release of PGE2  by the isolated ductus is stimulated by increasing 
oxygen (Clyman et al, 1980a; Coceani et al, 1986). Increasing oxygen 
actually decreases the activity of PGI2  synthase in the ductus (Needleman 
et al, 1981), possibly by stimulating the release of a hydroperoxy fatty 
acid with a direct inhibitory effect of the enzyme (Needleman et al, 1981; 
Powell, 1982). This is consistent with the effect of oxygen on PGE2: a 
decreased activity of PGI2  synthase would result in accumulation of PGH2  
which would then degrade to form PGE2. Oxygen may also act by the 
stimulation of free radical release, as the hydroxyl radical, but not super­
oxide anion, stimulates the release of dilator prostaglandins by the ductus 
(Clyman et al, 1989; Saugstad and Sanderud, 1989).
Relaxation of the ductus by PGE2  is associated with a rise in the 
intracellular concentration of cyclic adenosine monophosphate (cAMP) 
(Walsh and Mentzer, 1987). PGE2  acts, at least in part, by inhibiting the 
sensitivity of the contractile proteins to calcium (Crichton et al, 1994). As 
well as causing relaxation of the ductus, PGE2  inhibits myogenic tone 
(Kriska et al 1990) and may inhibit the response of the isolated ductus to 
noradrenaline, as the sensitivity of the ductus to noradrenaline is increased 
following incubation in indomethacin (Smith and McGrath, 1988). The 
effect of PGE2  decreases after birth in term animals (Momma et al, 1980; 
Clyman et al, 1983a). This decreased sensitivity is probably related to 
partially irreversible contraction (Clyman et al, 1983a) and it is less 
marked in pre-term neonates (Clyman et al, 1985).
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Only 2 studies have looked at contractile effects of prostanoids on the 
ductus. The first looked at the effect of a single very high concentration 
(about 7fiM) of PGF2a, which they found caused a small contraction of the 
ductus (Starling and Eliott, 1974). The other looked at the effect of a 
biogeneration system for TxA2  (incubation of PGG2  or PGH2  with 
microsomal fractions of human platelets or guinea pig lungs) on the ductus 
(Coceani et al, 1978a). Whereas PGG2  or PGH2  relaxed the ductus 
(presumably by formation of PGE2), when PGG2  or PGH2  were incubated 
in platelet or lung microsomes, they had no effect on the ductus arteriosus 
(lamb). The authors acknowledged the possibility that small quantities of 
PGE 2  were formed which may have masked effects (Coceani et al, 
1978a).
1.2.4 Non-prostanoid vasodilators.
Both sodium nitroprusside (SNP) and glyceryl trinitrate dilate the lamb 
ductus in vivo (Walsh et al, 1988) and in vitro (Walsh and Mentzer, 
1987). These agents increase the intra-cellular concentrations of both 
cAMP and cGMP in the ductus (Walsh and Mentzer, 1987) and, in the 
absence of indomethacin, their maximum effect on the oxygen-contracted 
ductus is greater than PGEj. I have observed that the rabbit ductus pre­
contracted with 10|iM noradrenaline relaxes in response to acetyl choline 
in the endothelium-intact but not endothelium-denuded ductus arteriosus 
(Smith GCS, unpublished observations), which is preliminary evidence for 
release of nitric oxide by the ductus.
Adenosine reverses the oxygen-induced contraction of the lamb fetus 
ventilated with oxygen in utero (Mentzer et al, 1985). Furthermore, the 
circulating concentrations of endogenous adenosine vary inversely with 
both the arterial oxygen tension and the degree of contraction of the 
ductus arteriosus (Mentzer et al, 1985). However, adenosine has no effect 
on the indomethacin-induced contraction of the fetal lamb (Friedman et 
al, 1983).
31
The ductus also has p adrenoceptors which mediate relaxation (Bodach et 
al, 1980). The contractile effect of adrenaline through a  adrenoceptor 
activation will, therefore, be offset somewhat by its dilator effect through p 
adrenoceptors. Nevertheless, the net effect of adrenaline in the isolated 
vessel in vitro is contractile (Kovalcik, 1963).
1.3 Closure of the ductus arteriosus.
1.3.1 Control systems in closure.
There is as yet no clear model of control of contraction of the ductus in the 
neonate. As discussed in section 1.2, there are a number of factors which 
control ductal smooth muscle and in most cases there is a clear pattern of 
inhibitory influences decreasing towards term and being eliminated after 
birth and contractile influences increasing towards term and being 
promoted following birth. However, the ductus is widely patent 
immediately prior to birth despite the changes that occur towards term. 
Furthermore, many of the factors identified as promoting contraction of the 
ductus at birth change very rapidly following birth which is in contrast to 
the slower closure of the ductus. A good example of this is the release of 
bradykinin from the lungs at birth, which had been proposed to be 
involved in the post-natal closure of the vessel (see section 1 .2 .2 ): the 
release of bradykinin is immediate, whereas the closure of the ductus is 
(relatively) delayed.
It seems likely that oxygen tension and PGE2  are central to the control of 
the ductus, as the two most remarkable features of the control of ductal 
smooth muscle are its profound contractile response to oxygen and its 
profound relaxant response to PGE2. However, it is not clear how these 
factors interact at birth. As discussed in section 1.2.3, increasing oxygen 
actually stimulates PGE2  release by the ductus. Any model of ductal 
closure will have to explain why the factor which is central to stimulating 
contraction of the vessel after birth (i.e. oxygen) causes the release of the 
factor central maintaining the vessel in a patent state in utero (i.e. PGE2).
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Finally, in considering the control systems regulating the ductus, the focus 
has been on the efferent, effector limb of the control model. The nature of 
the sensor and afferent limb has been somewhat neglected. Interestingly, 
the ductus has structures in its wall which are similar to the carotid and 
aortic bodies (Boyd, 1941; Fay, 1971; Macdonald et al, 1983) which send 
afferent fibres to the left vagus nerve (Boyd, 1941). Given the pressor 
innervation of the ductus (see 1 .2 .2 ), there may indeed be a neural control 
loop. Again, there is no model to link the action of the pressor nerves of 
the ductus with the effects of oxygen and PGE2 .
1.3.2 Anatomical aspects of ductal closure.
Closure of the ductus in the neonate has been thought of as consisting of 
two distinct processes: an initial, functional closure by contraction of 
ductal smooth muscle and a later, irreversible closure of the vessel by 
microanatomical changes in its structure (Heymann and Rudolph, 1975).
The anatomical changes have been considered in 4 stages (Gittenberger 
et al, 1985): (1) creation of an area of sub-endothelial oedema formed by 
separation of the endothelium from the internal elastic lamena (2 ) 
endothelial cell infolding and ingrowth with migration of undifferentiated 
smooth muscle cells from the inner media into the sub-endothelial layer, 
forming "sub-intimal cushions". (3) endothelial cell apposition (4) fibrotic 
degeneration of the vessel. The anatomical changes are promoted by 
indomethacin and inhibited by PGE2  (Mine, 1981), although ductal smooth 
muscle cell migration is inhibited by indomethacin in vitro (Koppel and 
Rabinovitch, 1993).
The theoretical dissociation of the functional and anatomical contraction 
of the ductus is a mistake. The ductus begins to close after a few hours of 
birth, even though the process takes 24 to 48 hours to be completed. Even 
the initial contraction of the ductus seems to be only partially reversible, 
which suggests that anatomical changes are taking place before the
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functional contraction is complete (Clyman et al, 1983a). Interestingly, 
the initial contraction of the pre-term ductus is fully reversible (Clyman et 
al, 1985), which suggests that the biological processes required for these 
anatomical changes following closure are not present in the pre-term 
animal and must develop towards term.
1.4 Clinical significance of the ductus arteriosus.
There are 3 main clinical situations where the therapeutic control of the 
ductus arteriosus is important. In two of these, useful clinical therapies 
were developed from basic pharmacological studies on animals, and the 
ductus arteriosus is a clear example of a situation where animal research 
has led to novel and important human drug development.
1.4.1 Patent ductus arteriosus.
As the name suggests, patent ductus arteriosus (PDA) is failure of the 
ductus to close soon after birth. There are two main groups of patients 
suffering from this: firstly, premature infants and, secondly, older children 
and adults. Closure of the ductus in the latter case is surgical. There is the 
option of drug treatment to close the ductus in premature infants which 
has arisen from an understanding of the vessel's basic pharmacology.
The treatment for PDA in premature infants was originally surgical ligation 
of the vessel. The disadvantages of this form of treatment were (1) the 
infants are small and often unwell (2 ) the required level of surgical 
expertise was only found in major centres, necessitating transfer of sick 
premature infants from smaller centres. The observation that indomethacin 
contracted the ductus arteriosus of lambs and rabbits led directly to its use 
in human infants and it is currently a widely used technique in closure of 
PDA (see Gersony, 1986 for review). The success rate of indomethacin is 
70%, compared with 35% for placebo. The major adverse effects of 
indomethacin are similar to the adult: renal impairment, gastro-intestinal
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bleeding and bleeding tendency (secondary to its effects on platelets). 
Recently, more sophisticated 'closed' surgical techniques of ductal closure 
have been developed, namely the Rashkind occluder (Rashkind et al, 
1987). The continued need for development of treatments reflects the 
relatively high failure rate of indomethacin and its adverse effects.
1.4.2 Ductus-dependent circulation.
The term "ductus-dependent circulation" applies to a diverse range of 
congenital heart defects where, as a consequence of the nature of the 
defect, continued patency of the ductus arteriosus of the neonate is 
necessary for its survival (see Freed et al, 1981). There are 3 roles that the 
ductus can have in such circumstances: ( 1 ) to maintain adequate 
pulmonary blood flow, e.g. in pulmonary atresia; (2 ) to maintain adequate 
systemic blood flow, e.g. in aortic arch abnormalities; and (3) to improve 
mixing of the systemic and pulmonary circulations, e.g. in transposition of 
the great arteries. The natural history of these conditions is that the infant 
is often healthy at birth, but then deteriorates in early neonatal life as the 
ductus closes. Formerly, detection of such a defect was an indication for 
emergency surgery before ductal closure was complete. The observation 
that PGE2  was a potent dilator of the lamb ductus led directly to the use of 
PGEj (or PGE2) to maintain artificially ductal patency until definitive 
surgery could be performed. This therapy results in often dramatic clinical 
improvement in infants with these diverse conditions. It is not effective, 
however, when closure of the ductus is complete and is most effective 
where the initial degree of closure is smallest (Clyman et al, 1983a). With 
the ability to diagnose congenital heart defects pre-natally, it has been 
suggested that ductal patency in infants with these conditions could be 
optimised by pre-natal diagnosis and then commencing therapy 
immediately following birth in affected infants (Smith, 1992).
Intravenous PGEj has major adverse effects, including apnoea (10-15%), 
pyrexia (10-15%), cardiac arrest, seizures/jitteriness, hypotension, flushing 
(10%) and diarrhoea (Gersony, 1986). These adverse effects are all the
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more serious since the infants are often unwell due to their cardiac defect. 
There is currently no alternative to the E series prostaglandins in the 
treatment of these conditions and the importance of the therapy is such 
that the adverse effects have to be accepted.
1.4.3 Pregnancy.
The use of non-steroidal anti-inflammatory drugs (NSAID) in pregnancy 
has been recently reviewed (Van den Veyver and Moise, 1993). One of the 
problems with these drugs in pregnancy is that they cross the placenta and 
contract the fetal ductus arteriosus. There are 3 main situations where they 
are used in pregnant women: ( 1 ) treatment of pre-existing medical disease, 
e.g. rheumatoid arthritis- generally, the NSAID would be substituted for a 
simple analgesic for the duration of pregnancy (2 ) treatment of premature 
labour- NSAIDs (indomethacin is most widely used) are uterine tocolytics; 
and, (3) treatment of polyhydramnios- NSAIDs (again, indomethacin is 
most widely used) decrease fetal urine output which decreases production 
of liquor.
Significant contraction of the ductus arteriosus is seen in over half of 
fetuses in the course of maternal administration of indomethacin for 
premature labour and the extent of contraction varies directly with the 
gestational age of the fetus (Moise et al, 1988). There are isolated reports 
of neonatal deaths apparently secondary to NSAID-induced contraction of 
the fetal ductus, although studies in pre-term labour suggest that 
constriction of the fetal ductus following maternal administration of 
indomethacin does not result in significant cardiovascular disease in the 
neonate (see Van den Veyver and Moise, 1993).
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1.5 Potential for drug development
1.5.1 Patent ductus arteriosus.
The effect of indomethacin on the ductus arteriosus is thought to be 
mediated entirely by elimination of the dilator effect of PGE2  (Clyman, 
1987; Coceani and Olley, 1988). A selective antagonist of the ductal PGE2  
receptor (EP receptor) would be expected, therefore, to be at least as 
effective a constrictor of the ductus as indomethacin. Furthermore, it is 
likely that most of the adverse effects of indomethacin (see above) are 
mediated by eliminating the effects of prostaglandins on different 
prostanoid receptors compared with its contractile effect on the ductus. A 
selective antagonist of the ductal EP receptor would not, therefore, be 
expected to have many of the adverse effects of indomethacin. 
Identification of the EP receptor sub-type mediating the effects of PGE2  on 
the ductus arteriosus would provide a clear strategy for the development 
of safer and more effective therapies in PDA.
1.5.2 Ductus-dependent circulation.
PGEj is a potent agonist of all the EP receptor sub-types (Coleman et al, 
1990). Although the EP receptor sub-types mediating the adverse effects 
of PGEj are unknown, it is highly unlikely that the same receptor mediates 
both the therapeutic effect of PGEj on the ductus arteriosus and all its 
diverse adverse effects. A selective agonist of the ductal EP receptor 
would be expected to be as effective as PGEj in ductus-dependent 
circulation, but with fewer adverse effects. Again, identification of the EP 
receptor sub-type mediating the effects of PGE2  on the ductus arteriosus 
may lead to the development of safer and more effective drugs in ductus- 
dependent circulation.
Furthermore, there is some evidence that the effect of PGE2  on the ductus 
is inhibited by increasing oxygen tension (Coceani et al, 1975). In 
ductus-dependent cyanotic congenital heart disease, PGEj increases
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arterial oxygen tension (Freed et al, 1981). If oxygen decreases the 
sensitivity of the ductus to PGE2, it may be that when PGEj is administered 
in these forms of heart defect, its therapeutic effect (i.e. increasing arterial 
oxygen tension) may decrease the sensitivity of its target (i.e. the ductus) 
to its action: i.e. there is potential for this therapy to be self-limiting. If this 
effect of oxygen is specific to PGE2, other vasodilators may be more 
appropriate in these situations.
Finally, it has been demonstrated in some experimental conditions that 
indomethacin increases the sensitivity of the ductus to PGE2  (Coceani et 
al, 1975). All the comparisons between PGE2  and other prostanoids were 
made in the presence of indomethacin (Clyman et al, 1978a and 1978c; 
Coceani et al, 1978b; Friedman et al, 1983) and this may have 
exaggerated the relative potency of PGE2  as a ductal dilator. There may be 
other agents which are equally effective dilators of the ductus but have 
fewer side-effects and could be used in ductus-dependent circulation.
1.5.3 Premature labour.
Indomethacin inhibits uterine contraction by eliminating contractile 
prostaglandin effects on the myometrium. The prostanoid receptors 
mediating these contractile effects on human myometrium are EPj, EP3, FP 
and TP (Senior et al, 1991, 1992). There are two theoretical approaches to 
this clinical problem to avoid contraction of the ductus: firstly, one could 
develop a selective prostanoid receptor antagonist which blocked one or 
more of the contractile receptors on myometrium but was without activity 
at the ductal prostanoid receptor(s); or, secondly, one could co-administer 
a selective agonist of the dilator EP receptor on the ductus with 
indomethacin to protect the vessel from indomethacin contraction. Both 
situations require that the dilator EP receptor on the ductus is different 
from the contractile EP receptors on the uterus, which requires 
characterisation of the ductal EP receptor.
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1.6 Aims of this work.
The aims of this work were directed at improving both the basic 
understanding of the physiology and pharmacology of closure of the 
ductus and identifying promising new avenues for the manipulation of the 
ductus in the clinical conditions discussed above. Clearly, there were areas 
of overlap between these two areas of study. The specific aims were as 
follows.
1 .6 . 1  Interactions between PGE2  and noradrenaline.
Research on the effect of endogenous and exogenous PGE2  on the ductus 
has focused on the effect of this drug on the vessel's intrinsic tone. I have 
demonstrated that indomethacin increases the sensitivity of the ductus to 
noradrenaline (Smith and McGrath, 1988), implying that PGE2  decreased 
the sensitivity of the ductus to noradrenaline. One aim of the study was to 
characterise the effect of PGE2  on the vessel's response to noradrenaline.
1.6.2. Interactions between PGE2  and oxygen.
As discussed in section 1.2.1, the two main factors in the physiological 
regulation of the ductus are PGE2  and oxygen tension. A major goal of this 
study was to characterise the relationship between oxygen tension and 
the vessel's response to PGE2, and to establish whether any effect of 
oxygen on PGE2  was specific to PGE2. Furthermore, I sought to establish 
whether the two factors which dilate the ductus in utero (low oxygen 
and high PGE2) interact together in controlling the vessel's response to 
noradrenaline. As well as shedding light on the physiological control of 
the vessel, these questions are of relevance to the therapeutic control of 
the ductus as discussed above.
1.6.3 EP receptor sub-type.
Perhaps the clearest avenue for drug development in the therapeutic 
control of the ductus is the use of selective agonists and antagonists of the 
EP receptor in the ductus arteriosus. As discussed above such drugs would
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be expected to be safer and more potent than existing therapies. One aim 
was, therefore, to characterise the dilator EP receptor on the fetal rabbit 
ductus arteriosus as a first step towards that goal.
1.6.4 Characterisation of the effect of other prostanoids.
The ductus synthesises a range of prostaglandins but so far there is only 
evidence for an effect of PGE2. This is at least partly due to a lack of good 
detailed quantitative studies on the effects of other prostanoids on the 
ductus. It is also explained by the fact that much of the early work on the 
ductus was carried out prior to the availability of the many synthetic 
prostanoids developed in recent years. I aimed to screen for the full range 
of known prostanoid receptors, contractile and relaxant, in the ductus.
1.6.5 Characterisation of the effect of indomethacin.
Indomethacin eliminates the effects of endogenous prostanoids 
synthesised by the ductus. From its effects, one can deduce the net effect 
of endogenous prostanoids synthesised by the ductus under any given set 
of physiological conditions. Thus, the effect of indomethacin may shed 
light on the physiological effect of prostaglandins synthesised in the wall 
of the ductus. Furthermore, comparison of the relative potencies of 
prostaglandins as dilators of the ductus has always been carried out in the 
presence of indomethacin, despite the fact that indomethacin has been 
shown to increase the vessel's sensitivity to PGE2  (Coceani et al, 1975). I 
sought to elucidate the mechanism of this effect of indomethacin on the 
vessel's response to PGE2  and to elucidate the effect of indomethacin on 
the sensitivity of the ductus to other prostanoid and non-prostanoid 
dilators.
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Chapter 2. General Methods.
The basic design of the study was as follows: the ductus arteriosus was 
isolated from fetal New Zealand White rabbits and mounted in vitro for 
the measurement of isometric tension. Contractile or relaxant responses 
were elucidated under varying experimental conditions, such as varying 
oxygen tension, or in the presence and absence of drugs (such as receptor 
antagonists, enzyme inhibitors etc.).
2.1 Preparation of tissue.
Time-mated pregnant New Zealand White rabbits were killed at 28 days 
gestation by intra-venous injection of a lethal dose of sodium 
pentobarbitone into an ear vein and exsanguination by bilateral laceration 
of the common carotid arteries. The fetuses were delivered by Caesarean 
section and decapitated prior to the onset of respiration. The thorax was 
opened and under dissection microscope, one or two rings of ductus 
arteriosus (1-1.5mm in length) were obtained from each fetus. The 
investigation was performed in accordance with the Home Office 
Guidance on the operation o f the Animals (Scientific Procedures) Act 
1986, published by Her Majesty's Stationery Office, London.
2.2 Experimental conditions.
Each ring of ductus arteriosus was suspended between two stainless steel 
hooks (one stable, the other connected to an isometric tension transducer 
[Grass, model FT 03C]). Passing the hooks through the narrow vessel 
lumen denuded it of endothelium, which was confirmed by light 
microscopy. The mounted vessels were placed in 10ml organ baths 
containing physiological salt solution (PSS) of the following composition 
(mM): NaCl 119, KC14.7, MgS04  1.0, KHP04  1.2, CaCl2  2.5, NaHC03  25.0, 
and glucose 11.0; with 23pM Na2EDTA when noradrenaline was being
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used. The signal from the transducer was relayed to a bridge conditioner 
(Fylde FE 492 BBS) and thence to a chart recorder (Linseis 7208).
The tension transducer was secured in a Vernier control (Hugo Sachs 
Electronics, type 850S) which allowed very accurate adjustment of its 
height relative to the preparation. By elevating or lowering the transducer, 
the degree of passive tension placed on the vessel could be altered and 
this could be monitored by the displacement of the pen of the chart 
recorder.
The vessels were maintained at 36.5-37°C. The baths were bubbled with 
gas mixtures of variable 0 2, 5% C02, and remainder N2. The gas mixtures 
were made up in a rotameter system (normally used for anaesthetic gas 
dispension), stored in Douglas bags and bubbled through the system by a 
small pump. When 2% 0 2  was used, the organ bath was partially covered 
with chemically inert film to reduce diffusion of oxygen from the air. In the 
experiments where 3% oxygen was used, special organ baths with narrow 
necks were used which made the film unnecessary. Temperature and 
oxygen tension were measured continuously in an additional organ bath 
which was validated by intermittent checks of temperature and oxygen 
tension in the other baths. The oxygen measuring system (0 2  electrode 
and 0 2  meter, Strathkelvin Instruments, model 781) was zeroed in a 0.01M 
solution of sodium borate saturated with sodium sulphite. The gain was set 
at 36.5 to 37°C bubbling with room air, after correction for atmospheric 
and water vapour pressure and assuming ambient oxygen of 20.93%.
2.3 Contractile and relaxant responses.
After an initial incubation period (typically 90 minutes) the response to 
agonists was studied. As most responses were in the presence of 
indomethacin (l|iM ) and this caused contraction of the vessel as 
previously described (see section 1.2.3), the vessel was generally relaxed
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by some means prior to obtaining a contractile response. When studying 
relaxations, the vessel was pre-contracted with one of the following: ( 1 ) 
IOjiM noradrenaline, (2) lfiM indomethacin plus lOpM noradrenaline or 
(3) l|iM  indomethacin plus 25mM K+. In all cases, a response (contractile 
or relaxant) under a given set of experimental conditions was compared 
with a similar number of concurrent, time-matched controls. The exact 
experimental protocol used for a given part of the study is detailed in each 
chapter.
2.4 Quantification of responses.
The potency of agonists was estimated by the pEC50, i.e. -log1 0 EC5 0  where 
the EC5 0  is the interpolated molar concentration of the drug causing 50% 
of its own eventual maximum response, either contractile or relaxant. An 
EC 5 0  was only calculated when the response to a given agonist was 
clearly maximal. In a small number of cases, the potency was expressed as 
the concentration required to cause a given decrease in the extent of pre­
contraction (Chapter 6  only, see section 6.1.3).
The maximum contractile response (MCR) to vasoconstrictors under a 
given set of conditions was generally expressed with reference to a control 
response. The maximum relaxant response (MRR) to a vasodilator was 
expressed in one of two ways: (1 ) as a percentage of a preceding control 
response, either to the same agonist under control conditions or a control 
response to a different agonist which was being used as a standard, or (2 ) 
as a percentage of the maximum relaxation as determined by addition of 
lOOnM PGE2  and 30pM papaverine at the end of the response, which 
resulted in loss of all active tone (i.e. below baseline and with no further 
response to lfiM forskolin).
In each chapter, the exact method used to quantify responses and the 
reason why a given method was used is made clear.
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2.5 Drugs.
The following drugs were used: adenosine, atrial natriuretic peptide (ANP, 
rat 1-28), forskolin, indomethacin, noradrenaline bitartrate, papaverine 
hydrochloride, propranolol hydrochloride, sodium nitroprusside (SNP, all 
Sigma); AH13205, AH23848B, AH6809 and GR63799X (Glaxo); 
BW245C and BW8 6 8 C (Wellcome); cicaprost and sulprostone (Schering); 
misoprostol and SC19220 (Searle); PGE2  (U-12062), PGF2a tromethamine 
salt (U-14583E) and U46619 (Upjohn); cromakalim (BRL 38227, Smith 
Kline Beecham); flubriprofen (Boots); nifedipine (Bayer); and EP 092 
(Edinburgh University). The stock solutions of drugs were as follows: 
PGE2  was in ethanol (lOmg/ml) which was diluted to 100pM in 0.1M 
phosphate buffer; BW245C was in ethanol (lOmg/ml) and the lOmM 
dilution was in 0.1M phosphate buffer; cromakalim (lOmM), nifedipine 
(lOmM), BW8 6 8 C (lOmM), GR63799X (lOmg/ml), misoprostol (ImM), 
SCI9220 (5mg/ml) and papaverine (20mM), were in ethanol; indomethacin 
(lOmM) and AH13205 (lOOmM) were in 10% NaHC03; AH6809 was in 
1% NaHC03  in 0.9% saline; sulprostone was in 3% v/v ethanol and 0.01% 
v/v Tween 80 (Sigma); noradrenaline (lOmM) was in 23|iM Na2 EDTA; 
forskolin (lOmM) was in DMSO; U46619 (lOmg/ml) was supplied in 
methyl acetate and diluted to 1 mg/ml in ethanol; adenosine (lOmM), ANP 
(10|iM), flubriprofen (ImM), PGF2a (ImM) and SNP (lOmM) were in 0.9% 
saline; cicaprost (0.5mg/ml) and propranolol (lOmM) were in distilled 
water. AH23848B was dissolved in 10% NaHCC> 3  which was then added 
to the appropriate volume of HC03-free PSS to result in PSS with the 
desired concentration of the drug and a [HC03] of 25mM. Solutions of 
indomethacin, nifedipine and SNP were protected from light. All 
subsequent dilutions were made in 0.9% saline, except noradrenaline 
which was diluted in 23pM EDTA. All drugs were stored on ice for the 
duration of the experiment.
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2.6 Statistics.
All data are expressed as means with either the standard error of the mean 
(SEM) or 95% confidence intervals (Cl) in parenthesis. In graphs, points 
are means, bars are SEM. Comparison of two means was made by Student’s 
t-test, paired or un-paired as appropriate, when the data was normally 
distributed. When the datawere not normally distributed, or where there 
were any doubt (especially with small numbers of observations) comparison 
was made by the Mann-Whitney U test, which is suitable for parametric 
and non-parametric data. Comparison of three or more means was made by 
analysis of variance (ANOVA). Multiple comparisons after ANOVA were 
made using Tukey’s method for calculating Cl (95%) of pairwise 
differences. Significance was assumed at the 5% level. Statistical analysis 
was performed on Minitab Release 8.2 for the Apple Macintosh.
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Chapter 3. Characterisation of experimental conditions for 
study of contractile and relaxant responses of fetal rabbit 
ductus arteriosus.
The standard animal for studies on the pharmacology of ductus arteriosus 
smooth muscle has tended to be the fetal lamb (Clyman, 1987). This 
preparation is limited by several facts: the animals are expensive, they are 
large and they have a long gestation. Very few studies have used the 
rabbit. However, the vessel of the fetus and neonate is sufficiently large to 
use as a standard organ bath preparation and is much cheaper and more 
convenient to use than the sheep. The studies on the rabbit are so limited, 
however, that there has been no detailed description of the ideal 
experimental conditions for the study of the rabbit ductus. I sought to 
characterise the optimum experimental conditions for the ductus arteriosus 
of the fetal rabbit at 28 days gestation.
3.1 Methods.
The general methods outlined in Chapter 2 were employed for setting up 
and maintaining rings of ductus arteriosus. All of the experiments 
described in this chapter were carried out in 15% oxygen, which resulted 
in an oxygen tension of 100-1 lOmmHg. Responses to agonists (contractile 
and relaxant) were obtained cumulatively, with a given response being 
allowed to attain a maximum level before eliciting the next.
3.1.1 Effect of stretch on responses.
Preparations of the vessel were initially stretched to 0.3g.tension which 
was re-set at 60 minutes. The PSS was changed at 30 and 60 minutes. At 
90 minutes, a standard contraction was obtained by exposing the vessel to 
a [K+] of 65mM using PSS where NaCl was isotonically replaced with KC1. 
This was washed out with three changes of PSS over 15 minutes and, once
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the tension had settled, the stretch of the vessel was altered to one of 6  test 
levels (g.tension): 0.1, 0.2, 0.3, 0.6, 0.9 and 1.2. 30 minutes later, 
indomethacin was added to the bath (lfiM) and after a further 30 minutes, 
2M KC1 was added to the bath to give a final [K+] of 25mM. After 10 
minutes exposure to the increased [K+], a cumulative, concentration 
relaxation response curve (CRRC) to PGE2  was obtained. Following this, 
the PSS was changed three times over 15 minutes and the vessel was 
incubated in lfiM indomethacin for 30 minutes. The vessel was then 
relaxed with InM PGE2  and a cumulative concentration contraction 
response curve (CCRC) was obtained to noradrenaline. The last part of 
that protocol was repeated and a second CCRC to noradrenaline was 
obtained in lOnM PGE2.
The magnitude of contractile and relaxant responses at the different 
degrees of test stretch was related to the control response to 65mM K+ at 
the standard degree of stretch of 0.3g.tension. The sensitivity to 
contractile and relaxant agonists was quantified by the pEC5 0  (see section
2.4 for definition).
3.1.2 Effects of stretch on the time dependence of responses.
The time-dependence of the response to noradrenaline was studied with 
the vessel set up at initial preparation with 3 different levels of stretch 
(g.tension): 0.2, 0.6 and 1.2. It was incubated for 90 minutes and the PSS 
changed at 30 and 60 minutes. Following this, a series of 4 or 5 
consecutive CCRC to noradrenaline was obtained. The PSS was changed 
3 times after each response and at least 45 minutes allowed between 
responses. This was carried out in the absence of indomethacin and 
exogenous PGE2. In addition, a protocol was used where the vessel was 
stretched to 0 .2 g.tension at initial preparation and consecutive responses 
to noradrenaline were obtained by the same time course described above, 
but responses were elicited in the presence of ljxM indomethacin (added at 
least 30 minutes prior to the CCRC) and InM PGE2  (added 10 minutes
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prior to the CCRC).
The time-dependence of the CRRC to PGE2  was studied with the vessel 
stretched to 0.6g.tension and re-set at 60 minutes. The PSS was changed 
at 30 and 60 minutes. Indomethacin was added at 90 minutes and 30 
minutes later, 2M KC1 was added to a bath [K+] of 25mM. After a further 
10 minutes, a CRRC to PGE2  was obtained. The protocol was repeated to 
obtain 3 consecutive CRRC to PGE2. The PSS was changed 3 times after 
each response and at least 55 minutes allowed between responses.
3.2 Results.
The magnitude of the contractile response to indomethacin increased as 
the degree of stretch was increased from O.lg.tension to 0.6g.tension and 
was steady between 0.6 to 1.2g.tension. (Figure 3.1). The pEC5 0  to PGE2  
was the same across the range of stretch (Figure 3.2). The maximum 
relaxant response (MRR) to PGE2  varied with the degree of stretch in a 
similar pattern to the contractile response to indomethacin (Figure 3.3). 
The degree of stretch had no effect on the pEC5 0  of the ductus to 
noradrenaline, both in InM and lOnM PGE2, or on the magnitude of 
change in pEC5 0  to noradrenaline-induced by increasing PGE2  from InM 
to lOnM (Figure 3.4). The maximum contractile response (MCR) to 
noradrenaline, in both InM and lOnM PGE2, varied with the degree of 
stretch in a similar pattern to the response to indomethacin, but the 
magnitude of the difference in the MCR comparing InM and lOnM PGE2  
did not vary with the degree of stretch (Figure 3.5).
The sensitivity of the vessel to noradrenaline declined over a series of 
consecutive responses. This was related to the degree of stretch. With an 
initial stretch of 0 .2 g.tension, the first response to noradrenaline was more 
sensitive than subsequent responses, which were all similar (Figure 3.6). A 
very similar pattern was observed (0.2g.tension) when each CCRC was 
carried out in the presence of lpM indomethacin and InM PGE2  (Figure
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3.7). With the vessel initially stretched to 0.6 or 1.2g.tension, there was a 
steady decline in sensitivity to noradrenaline over the course of a series of 
consecutive responses (Figure 3.8). The maximum response to 
noradrenaline was the same over the course of the responses in all cases.
The sensitivity of the ductus to PGE2  was unchanged over the course of 3 
responses with a degree of stretch of 0.6g.tension (Figure 3.9). The 
magnitude of relaxation induced by PGE2  was also stable.
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Figure 3.1 The effect of stretch on the magnitude of contraction elicited 
by indomethacin. The magnitude of the response to indomethacin is 
expressed as a proportion of the control response to 65mM K+ at 
0.3g.tension. Means are significantly different from each other (ANOVA: F 
ratio 9.95, p<0.001). Multiple comparisons (Tukey's method), all numbers 
g.tension: 0.1 significantly less than 0.3 to 1.2; 0.2 significantly less than 
0.6 to 1.2; no other significant differences. See Appendix (Table A.l) for 
table of values of 95% Cl of pairwise differences. Points are means, bars 
are SEM. n=7-8.
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Figure 3.2 The effect of stretch on the pEC5 0  to PGE2. There is no 
significant difference between the means (ANOVA: F ratio 1.43, p=0.235). 
Points are means, bars are SEM. n=7-8.
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Figure 3.3 The effect of stretch on the maximum relaxant response 
(MRR) to PGE2. The magnitude of the MRR to PGE2  is expressed as a 
proportion of the control response to 65mM K+ at 0.3g.tension. Means are 
significantly different from each other (ANOVA: F ratio 20.01, p<0.001). 
Multiple comparisons (Tukey's method), all numbers g.tension: 0.1 
significantly less than 0.3 to 1.2g; 0.2 significantly less than 0.6 to 1.2g; 
0.3 significantly less than 0.6 to 1.2; no other significant differences. See 
Appendix (Table A.2) for table of values of 95% Cl of pairwise differences. 
Points are means, bars are SEM. n=7-8.
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Figure 3.4 The effect of stretch on the pEC5 0  to noradrenaline in lpM  
indomethacin and 1 or lOnM PGE2. (O InM PGE2  □  lOnM PGE2) Data 
for the two concentrations of PGE2  at a given degree of stretch are from 
the same vessels, the response in lOnM elicited second (see section 3.1.1 
for details of protocol). There was no significant difference in pEC5 0  
between the different degrees of stretch in InM PGE2  (ANOVA: F ratio 
1.44, p=0.232) and lOnM PGE2  (F ratio 0.33, p=0.894). The extent of 
change in pEC5 0  comparing the response in lOnM PGE2  with that in InM 
PGE2  was not significantly different comparing the different degrees of 
initial stretch (F ratio 2.01, p=0.098). Points are means, bars are SEM. n=7- 
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Figure 3.5 The effect of stretch on the maximum contractile response 
(MCR) to noradrenaline in lpM indomethacin and 1 or lOnM PG£2.
(O  InM PGE2  □  lOnM PGE2) The magnitude of the MCR to 
noradrenaline is expressed as a proportion of the control response to 
65mM K+ at 0.3g.tension. Data for the two concentrations of PGE2  at a 
given degree of stretch are from the same vessels, the response in lOnM 
elicited second (see section 3.1.1 for details of protocol). The MCR to 
noradrenaline was different with the degree of initial stretch in both InM 
PGE2  (ANOVA: F ratio 14.02, p<0.001) and lOnM PGE2  (F ratio 7.51, 
p<0.001). Multiple comparisons (Tukey's method), all numbers g.tension: 
InM PGE2: 0.1 significantly less than 0.3 to 1 .2 ; 0 . 2  significantly less than 
0.6 to 1.2; 0.3 significantly less than 0.6; no other significant differences. 
lOnM PGE2: 0.1 significantly less than 0.6 to 1.2; 0.2 significantly less 
than 0.6; no other significant differences. See Appendix (Tables A.3 and 
A.4) for table of values of 95% Cl of pairwise differences. The extent of 
change in MCR comparing the response in lOnM PGE2  with that in InM 
PGE2  was not significantly different comparing the different degrees of 
stretch (F ratio 0.67, p=0.648). Points are means, bars are SEM. n=7-8.
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Figure 3.6 The pEC 5 0  for 5 consecutive responses to noradrenaline 
(NA) with an initial degree of stretch of 0.2g.tension and in the absence 
of indomethacin and exogenous PGE2. The first pEC5 0  was significantly 
elevated compared to all the others (all p<0.0001). The second pEC5 0  was 
elevated compared with responses 3 to 5 (mean difference 0.169 [SEM 
0.036], p<0.0001). There was no significant difference in the pEC5 0  
between responses 3-5. Points are means, bars are SEM, n=7-13.
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Figure 3.7 The pEC5 0  for 5 consecutive responses to noradrenaline 
with an initial degree of stretch of 0.2g.tension and in lpM  
indomethacin and InM PGE2. The first pEC5 0  was significantly elevated 
compared with all the others (all p<0.0001). There were no significant 
differences in the pEC5 0  of responses 2 to 5. Points are means, bars are 
SEM, n=8 .
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Figure 3.8 The pEC5 0  for consecutive responses to noradrenaline with 
an initial degrees of stretch of 0 .6 g.tension or 1 .2 g.tension and in the 
absence of indomethacin and exogenous PGE2. O  = 0 .6 g (n=4); □  = 
1.2g (n=4). Points are means, bars are SEM.
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Figure 3.9 pEC5 0  to PGE2  over 3 consecutive responses with an initial 
stretch of 0.6g.tension, pre-contracted with lpM  indomethacin and 
25mM K+. There was no significant difference in the pEC5 0  comparing 
responses 2 and 3 with the initial response (Student’s paired t-test, 
p=0.053 and p=0.33 respectively). Points are means, bars are SEM, n= ll.
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3.3 Discussion.
The main finding of this series of experiments was that the degree of initial 
stretch had relatively little effect on the sensitivity of the ductus to 
agonists (as measured by the pEC50), both contractile (noradrenaline) and 
relaxant (PGE2), but that it did alter the magnitude of responses to given 
agonists. The exception to this was in time-dependent changes in 
sensitivity. With smaller degrees of initial stretch the first response to 
noradrenaline was more sensitive than the others (Figures 3.6). This was 
not due to changes in the vessel’s production of prostaglandins, as the 
same pattern was observed in lpM indomethacin and InM PGE2  (Figure 
3.7). With greater degrees of stretch, the sensitivity of the vessel to 
noradrenaline continued to change over 5 responses (Figure 3.8). 
Interestingly, with a degree of stretch (0.6g.tension) which was associated 
with a consistent decline in sensitivity to noradrenaline over the course of 
serial responses (Figure 3.3), the response to PGE2  was relatively stable 
with respect to time (Figure 3.9). Other than excluding a role for 
prostaglandins, no light was shed on the mechanism of these changes with 
time.
In practical terms, this work led to the use of certain fixed protocols:
(1) CRRC: tension was initially set at 0.6g.tension, re-set at 60 minutes and 
not altered thereafter;
(2) CCRC to noradrenaline: tension was initially set at 0.2g.tension, and 
not altered thereafter. This degree of stretch resulted in slightly smaller 
responses, a disadvantage outweighed by the greater time stability of 
sensitivity of responses compared with greater degrees of stretch.
(3) CCRC to noradrenaline: the second CCRC was used as the control 
response in view of the data in Figures 3.6 and 3.7.
Furthermore, in all situations where any form of quantitative comparison 
was being made (e.g. between two agonists or to a given agonist in the
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presence and absence of an antagonist) the test response was always 
compared to a similar number of appropriate concurrent time controls.
As well as the practical implications of these data, they also shed some light 
on the contractile properties of the isolated ductus arteriosus. The 
contraction elicited by indomethacin has been described previously in the 
lamb and is exploited clinically in the treatment of patent ductus arteriosus 
(see Chapter 1). This contraction is, however, mechanistically quite 
different from that induced by standard contractile agonists such as 
noradrenaline. Indomethacin is not an agonist for a receptor coupled to a 
stimulatory second messenger system. It inhibits cyclo-oxygenase and 
eliminates the effect of prostaglandins (Smith et al, 1991). The net effect 
of prostaglandins on the ductus are inhibitory and, therefore, indomethacin 
induces contraction of the vessel by eliminating an inhibitory influence 
(see Chapter 1). It follows from this, therefore, that the determinants of the 
magnitude of the indomethacin contraction include ( 1 ) the extent of 
synthesis of prostaglandins by the vessel (2 ) the sensitivity of the vessel to 
the inhibitory effects of prostaglandins (3) the degree of spontaneous tone 
present in the vessel.
This last point is clearly vital. Some authors have concluded in previous 
studies that the failure of indomethacin to induce a contraction reflects an 
absence of inhibitory effects of prostaglandins (Clyman et al, 1980a). 
However, if the vessel was producing very high concentrations of 
prostaglandins and was very sensitive to their inhibitory effects, 
indomethacin would still only produce a contraction if the vessel had some 
spontaneous tone present.
Considering the present experiments, the tone present in the vessel prior to 
the addition of indomethacin would have been from two sources: firstly, 
myogenic tone; and, secondly, oxygen-induced tone. It has been 
demonstrated in the isolated ductus arteriosus (both rabbit and guinea pig)
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that stretch of the vessel, either as a ring preparation or perfused vessel, 
induces myogenic tone (Ikeda et al, 1973a; Kriska et al, 1990). 
Furthermore, the myogenic response is inhibited by endogenous and 
exogenous prostaglandins (Kriska et al, 1990). It may be that the 
increasing response of the vessel to indomethacin with stretch reflects 
increased myogenic tone. Considering oxygen-induced tone, increasing 
oxygen tension in the range of 0-140mmHg oxygen contracts the ductus 
(see section 1.2.1). The response to indomethacin in Figure 3.1 was in 100- 
llOmmHg oxygen and would from Fay's paper of 1971 (Figure 8 ) be 
associated with over 80% of maximum oxygen-induced tone. 
Indomethacin removes prostaglandin inhibition of oxygen-induced 
contraction by the ductus. The extent of the indomethacin contraction 
may well simply reflect the oxygen-induced contraction. Stretch may well 
have increased the indomethacin contraction by putting the vessel at the 
optimal point in the length-tension curve for contractile responses of the 
vessel. This is supported by the fact that there was a similar relationship 
between stretch and the MCR to noradrenaline (Figure 3.5). Alternatively, 
stretch may have altered the response of the ductus to indomethacin by 
altering its synthesis of or sensitivity to prostaglandins.
Of the various possibilities, I demonstrated that stretch had no effect on the 
sensitivity of the ductus to PGE2  (Figure 3.2). The effect of stretch on the 
MRR to PGE2  (Figure 3.3) reflects the amount of active tone: PGE2  caused 
complete relaxation of the ductus under these circumstances, as indicated 
by a fall below baseline and no further response to lpM  forskolin (data not 
shown). With respect to dissecting out the other factors which may 
mediate the change in contractile responses with stretch, I did not pursue 
these experiments (e.g. repeating the experiments of Figures 3.1-3.5 in 0 
mmHg oxygen): interesting as these questions are, they fell outwith my 
primary aims and this work fulfilled the limited goal of providing validated 
experimental conditions for studies on the physiological and 
pharmacological properties of isolated rings of ductus arteriosus.
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C hapter 4. F u n ction a l ch a ra cter isa tio n  o f  d ila to r  
prostanoid receptors on the ductus arteriosus.
As discussed in Chapter 1, a major goal of this work was to characterise the 
dilator prostanoid receptors on the ductus arteriosus. As PGE2  is the most 
potent prostaglandin in dilating the vessel, it can be assumed that the 
ductus has a dilator EP receptor. I wished to identify which of the 4 sub- 
types of EP receptor was present on the ductus. Secondly, it has been 
suggested that PGE2  is the only prostaglandin important in the control of 
ductus arteriosus smooth muscle (Clyman, 1987; Coceani and Olley, 1988). 
This hypothesis predicts that the ductus would not have inhibitory 
receptors for any of the other prostaglandins. I wished to test this 
hypothesis.
Since much of the early work on the ductus was carried out, a large 
number of synthetic prostanoids have been developed with selective 
agonist and antagonist effects on prostanoid receptors (see Coleman et 
al, 1990 and 1994b for reviews). From these, I selected a range of 
agonists and antagonists which had relatively selective activity at EP 
receptor sub-types. There is no selective EP4  agonist, however, the 
agonists used had activity at one or more of the other sub-types (see 
section 4.3 for references): misoprostol (EP2  and EP3), sulprostone (EPj 
and EP3), GR63799X (EPj and EP3), and AH13205 (EP2). Furthermore, 
three EP antagonists were available: AH6809 (EPj), SC19220 (EPj) and 
AH23848B (EP4). The non-EP prostanoid receptors which mediate 
relaxation of smooth muscle are IP and DP (Coleman et al, 1990). The 
selective IP agonist, cicaprost, was used and both a selective agonist and 
antagonist of the DP receptor were available (BW245C and BW8 6 8 C, 
respectively; see section 4.3 for references). Using these pharmacological 
tools I sought to characterise the inhibitory prostanoid receptors on the 
ductus arteriosus.
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4.1 Methods.
The general methods described in Chapter 2 were employed, which also 
gives the details of drug solutions.
The rings of ductus arteriosus were mounted in vitro and bubbled with 
15% oxygen, which resulted in an oxygen tension of 100-1 lOmmHg. The 
vessels were stretched to 0 .6 g.tension initially and this was re-set at 60 
minutes, and not altered thereafter. The PSS was changed at 30 and 60 
minutes following mounting and the vessels were allowed to incubate for 
90 minutes prior to addition of indomethacin. The vessel was pre­
contracted with IjiM indomethacin and, after a minimum of 30 minutes 
exposure to indomethacin, by addition of 2M KC1 to a bath [K+] of 25mM. 
Indomethacin tended to cause contraction with an unstable baseline, 
making it, on its own, a poor method of pre-contracting the rabbit ductus. 
The combination of lpM  indomethacin and 25mM K+ resulted in a 
sustained, stable elevation of tension. Concentration relaxation response 
curves (CRRC) were obtained cumulatively, with at least 55 minutes 
between successive curves. The effect of a given concentration of drug 
was allowed to reach a maximum before addition of the next. The PSS was 
changed at least 3 times after each CRRC. The first CRRC was a control 
response to PGE2 . The potency of agonists from subsequent
CRRC was expressed with reference to this initial response to PGE2 .
The potency of agonists was quantified relative to PGE2  by the 
equieffective molar ratio (EMR): the EC5 0  of the test agonist / the EC5 0  of 
PGE2  from the preceding control response, (see section 2.4 for definition of 
EC5 0 ). The response to a given concentration of agonist and its eventual 
maximum response were expressed as a proportion of the maximum 
response to PGE2  in the initial, control CRRC (Coleman, 1987). All 
estimates of potency were validated by comparison with
concurrent time controls to PGE2 .
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Antagonist activity was quantified as a molar concentration ratio (CR), 
defined as the EC5 0  of the agonist in presence of antagonist/ EC5 0  of the 
agonist in absence of antagonist. Where a significant effect was observed, 
data were obtained to construct a Schild plot from which a slope and pA2  
were determined (Arunlakshana and Schild, 1959). All estimates of the 
effects of antagonists were compared to concurrent time controls to the 
same agonist in the presence of the appropriate concentration of 
antagonist vehicle.
4.2 Results.
PGE 2  (0.03-10nM) potently relaxed preparations of rabbit ductus 
arteriosus in a concentration-dependent fashion (EC5 0  =0.36nM, see 
Figure 4.1). The highest concentrations of PGE2  (3-1 OnM) caused 
complete inhibition of the vessel’s tone. Furthermore, all of the synthetic 
EP receptor agonists tested, with the exception of sulprostone, relaxed the 
ductus although none was as potent as PGE2  and AH13025 produced no 
more than 2 0 % of the response to PGE2  at the highest concentration 
tested (100pM) (Figure 4.2 and Table 4.1). The rank order of potency of 
the agonists was: PGE2  »  misoprostol > GR63799X »  AH13205 > 
sulprostone > 0 .
The EPj receptor blocking drugs, AH6809 (10|iM) and SCI9220 (30|xM), 
both caused small apparent leftward shifts of the PGE2  CRRC compared 
with the preceding control response to PGE2  (mean CR [SEM]= AH6809 
0.78 [0.12], n= ll; SC19220 0.68 [0.12], n= ll) but the changes were not 
significant when compared with concurrent time controls (mean CR 
[SEM]= AH6809 1.09 [0.19] n=10, p=0.18; SC19220, 1.05 [0.17] n= ll, 
p=0.092).
The selective EP4  antagonist, AH23848B (10-100p,M), caused a 
concentration-dependent rightward shift of the PGE2  CRRC (Figure 4.3).
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The shift of the curves to PGE2  did not appear to be parallel and, 
furthermore, the slope of the Schild plot of these data (1.46, Figure 4.4) 
was significantly greater than unity. While AH13205 was only a weak 
dilator of the ductus (Figure 4.2 and Table 4.1) it did antagonise the 
response of the vessel to PGE2 , causing parallel rightward shifts of the 
PGE2  CRRC (Figure 4.5) and the slope of the Schild plot (Figure 4.6) was 
1.01.
The selective IP agonist, cicaprost, and DP agonist, BW245C, both caused 
complete relaxation of the ductus (Figures 4.7 and 4.8, respectively). 
Cicaprost was approximately 100-fold less potent than PGE2  and 
BW245C almost 900-fold less potent than PGE2  (Table 4.1). The 
sensitivity of the ductus to both these agonists was reduced by 30p,M 
AH23848B (Figures 4.9 and 4.10, respectively). The decrease in sensitivity 
to PGE2  induced by 30pM AH23848B (mean CR [SEM]= 6.53 [2.0], 
n=12) was significantly greater than that to cicaprost (p=0.04), but not 
significantly different from that to BW245C (p=0.097).
AH 13205 (30|iM) had no effect on the sensitivity of the ductus to 
cicaprost (Figure 4.11) but did cause a rightward shift in the CRRC to 
BW245C which was significantly greater than concurrent time controls 
(Figure 4.12). The effect of 30p,M AH13205 on the sensitivity of the 
ductus to PGE2  (mean CR [SEM]= 4.38 [1.2] was significantly less than on 
BW245C (p=0.046), but pooling the time controls to BW245C 
demonstrated a spontaneous 2.0 fold decrease (95% Cl 1.3-2.7) in 
sensitivity to BW245C between two consecutive responses to BW245C.
The selective DP receptor antagonist, BW8 6 8 C (10|xM), appeared to cause 
a slight shift to the right of the CRRC to BW245C (mean CR [SEM]= 3.76 
[0.87], n=6 ) but this was not significantly greater than seen in concurrent 
time controls (mean CR [SEM]= 2.27 [0.87], n=5; p=0.26).
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= 6  min= 1 2  min
Figure 4.1 Typical cumulative concentration relaxation response 
curve curve to PGE2  (0.03nM-10nM) in ljiM indomethacin and 25mM
K +. The 6  minute time bar refers to the PGE2  CRRC. lpM  INDO = 
addition of indomethacin to a final bath concentration of IjiM.
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Figure 4.2 The dilator effect of a range of EP agonists in lpM  
indomethacin and 25mM K+. Mean CRRC to PGE2  (O), misoprostol (□), 
GR63799X ( • ) ,  AH13205 (A) and sulprostone (■). All n>8 . Relaxation to 
PGE2  is expressed as a proportion of its own maximum and relaxation to 
other agonists is expressed as a proportion of the preceding control 
response to PGE2. Points are means, bars are SEM.
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Agonist EC 5 0 , nM (95% Cl)a EMR (95% CI)b n
PGE2 0.36 (0.32-0.41) [1 ] 44
Misoprostol 54 (37-71) 145 (73-217) 8
GR63799XC 239 (164-314) 685 (427-944) 8
Sulprostone^ >3,300 > 1 0 , 0 0 0 1 2
AH13205d >1 0 0 , 0 0 0 > 1 0 0 , 0 0 0 8
Cicaprost 28 (18-38) 110(80-140) 8
BW245C 312 (180-444) 875 (677-1074) 7
TABLE 4.1. Response to synthetic prostanoids in l|xM indomethacin 
and 25mM K+.
a EC5 0  = see section 2.4 for definition.
^EMR= equieffective molar ratio (see section 4.1 for definition). 
cMaximum response GR63799X = 87% (95% Cl 80-95) of maximum 
response to PGE2 . All other agonists, where EC5 0  given, maximum 
response was not significantly less than PGE2.
^Full CRRC not obtained.
Concurrent time controls to PGE2, obtained for all experiments, showed no 
spontaneous change with time (mean EMR= 1.07 [95% Cl 0.87-1.27], 
n=37)
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Figure 4.3 The effect of AH23848B on the response to PGE2.
Consecutive CRRC to PGE2 : control (O); in the presence of AH23848B 
10|iM ( • ) ,  30pM (■) and 100|xM (A). n=12. Relaxation to PGE2  in the 
absence of AH23848B (control response) is expressed as a proportion of 
its own maximum and relaxation to PGE2  in the presence of AH23848B is 
expressed as a proportion of the preceding control response to PGE2. 
Points are means, bars are SEM. Concurrent time controls to PGE2  (n=8 ) 
showed no spontaneous rightward shift (mean CR [SEM]= lOpM 0.95 
[0.16]; 30pM 1.10 [0.15]; lOOpM 1.09 [0.20], all p>0.5 compared with 
initial control response).
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Figure 4.4 Schild plot of the effect of AH23848B on the response to 
PGE2. Data obtained from responses displayed in Figure 4.3. Equation of 
line: log (CR-1) = 7.17 + 1.46 log [AH23848B]. Slope of line 1.46 (95% Cl 
1.13 to 1.78); pA2  = 4.91 (95% Cl 4.36 to 5.51).
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Figure 4.5 The effect of AH13205 on the response to PGE2.
Consecutive CRRC to PGE2 : control (O); in the presence of AH13205 
lOpM ( • )  30pM (■) and 100pM (A). n=7. Relaxation to PGE2  in the 
absence of AH13205 (control response) is expressed as a proportion of its 
own maximum and relaxation to PGE2  in the presence of AH13205 is 
expressed as a proportion of the preceding control response to PGE2. 
Points are means, bars are SEM. Concurrent time controls to PGE2  (n=5) 
showed no spontaneous change (mean CR [SEM]= 10|iM 0.92 [0.12]; 
30pM 0.81 [0.11]; lOOpM 1.22 [0.19], all p>0.1 compared with initial 
control response).
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Figure 4.6 Schild plot of the effect of AH13205 on the response to 
PGE2. Data obtained from responses displayed in figure 4.5. Equation of 
line: log (CR-1) = 4.89 + 1.01 log [AH13205]. Slope of line 1.01 (95% Cl 
0.52 to 1.49); pA2  = 4.85 (95% Cl 3.98 to 5.96).
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Figure 4.7 The effect of cicaprost in lpM indomethacin and 25mM K+.
Mean CRRC to PGE2  (O) and cicaprost ( • ) .  n=8 . Relaxation to PGE2  is 
expressed as a proportion of its own maximum and relaxation to cicaprost 
is expressed as a proportion of the preceding control response to PGE2. 
Points are means, bars are SEM.
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Figure 4.8 The effect of BW245C in lpM  indomethacin and 25mM K+.
Mean CRRC to PGE2  (O) and BW245C ( • ) .  n=7. Relaxation to PGE2  is 
expressed as a proportion of its own maximum and relaxation to BW245C 
is expressed as a proportion of the preceding control response to PGE2. 
Points are means, bars are SEM.
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Figure 4.9 The effect of 30|iM AH23848B on the response to cicaprost
Mean CRRC to cicaprost in the absence (O) and presence ( • )  of 30pM 
AH23848B. Relaxation to cicaprost in the absence of AH23848B (control 
response) is expressed as a proportion of its own maximum and relaxation 
to cicaprost in the presence of AH23848B is expressed as a proportion of 
the preceding control response. Points are means, bars are SEM. Mean CR 
(SEM) to cicaprost in 30pM AH23848B, 1.72 (0.29), n=7; vs time control, 
0.78 (0.05) n=7; p=0.019.
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Figure 4.10 The effect of 30[iM AH23848B on the response to 
BW245C. Mean CRRC to BW245C in the absence (O) and presence ( • )  
of 30pM AH23848B. Relaxation to BW245C in the absence of 
AH23848B (control response) is expressed as a proportion of its own 
maximum and relaxation to BW245C in the presence of AH23848B is 
expressed as a proportion of the preceding control response. Points are 
means, bars are SEM. Mean CR (SEM) to BW245C in 30pM AH23848B 
11.6 (2.1), n=8 ; vs time control 1.98 (0.48) n=6 , p=0.0027).
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Figure 4.11 The effect of 30pM AH13205 on the response to cicaprost
Mean CRRC to cicaprost in the absence (O) and presence ( • )  of 30pM 
AH13205. Relaxation to cicaprost in the absence of AH13205 (control 
response) is expressed as a proportion of its own maximum and relaxation 
to cicaprost in the presence of AH13205 is expressed as a proportion of 
the preceding control response. Points are means, bars are SEM. Mean CR 
(SEM) to cicaprost in 30pM AH13205, 1.04 (0.08) n=6 ; vs time control, 
0.93 (0.21) n=5; p=0.64.
-9 -8 -7 -6 -5 -4
log [BW245C]
Figure 4.12 The effect of 30|xM AH13205 on the response to BW245C.
Mean CRRC to BW245C in the absence (O) and presence ( • )  of 30|iM 
AH13205. Relaxation to BW245C in the absence of AH13205 (control 
response) is expressed as a proportion of its own maximum and relaxation 
to BW245C in the presence of AH13205 is expressed as a proportion of 
the preceding control response. Points are means, bars are SEM. Mean CR 
(SEM) to BW245C in 30pM AH13205 7.73 (0.87) n=6 ; vs time control 
1.80 (0.36), n=6 ; p=0.0007.
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4.3 Discussion.
It is now well established that receptors for PGE2  (EP receptors) may be 
subdivided into at least 3 subtypes, EPj, EP2  and EP3  (Coleman et al, 
1990). This classification is supported by both selective agonists and the 
EPj receptor blocking drugs, AH6809 and SC19220. More recently, a 
further type of EP receptor, the EP4  receptor, has been described which is 
characterized by a low potency of the existing range of synthetic agonists 
(Coleman et al, 1994a), and weak, but specific antagonist activity by the 
TP receptor blocking drug, AH23848B, which has no effect on EPj, EP2, or 
EP3  receptors (Coleman et al, 1994a).
The sensitivity of the ductus to PGE2  was unaffected by the EPj receptor 
antagonists, AH6809 and SCI9220, in concentrations 10-fold greater than 
any previously reported pA2  (Coleman, 1987), which indicates that PGE2  
does not dilate the vessel through the EPj receptor. This is supported by 
the absence of any dilator effect of the potent EPj agonist sulprostone 
(Coleman et al, 1990; Figure 4.2).
The weak dilator action of the selective EP2  agonist, AH13205 (Nials et 
al, 1993), indicates that PGE2  does not act through EP2  receptors on the 
rabbit ductus. In a range of EP2  containing tissues, this agonist has been 
reported to be 10- to 100-fold less potent than PGE2  (Nials et al, 1993), 
whereas in the rabbit ductus, this difference is at least 100,000-fold (Figure
4.2 and Table 4.1). This interpretation is supported by the fact that 
misoprostol is more than 100-fold less potent than PGE2  on the ductus 
(Figure 4.2 and Table 4.1), whereas it is almost equipotent with PGE2  at 
EP2  receptors in other tissues (Bunce et al, 1990).
Both sulprostone and GR63799X are actually more potent than PGE2  on a 
range of preparations containing EP3  receptors (Coleman et al, 1987; 
Bunce et al, 1990), but were substantially less potent than PGE2  on the
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ductus (Figure 4.2 and Table 4.1). Thus, it is unlikely that the dilator effect 
of PGE2  is mediated by the EP3  receptor.
AH23848B caused a rightward shift in the PGE2  CRRC (Figure 4.3) 
consistent with antagonism of the ductal EP receptor. The drug also had a 
small, additional non-specific effect, as evidenced by the nature of its effect 
on PGE2  (slope of Schild plot >1.0, Figure 4.4) and its small effect on 
cicaprost (Figure 4.9). AH23848B also blocks the putative EP4  receptors 
on pig saphenous vein (Coleman et al, 1994a). My findings with selective 
EP receptor agonists and antagonists suggest, therefore, that the dilator EP 
receptors on the ductus are of the recently described EP4  subtype. 
Alternatively, they may represent a novel subtype of EP receptors. The 
finding that AH 13205 was a selective antagonist of the ductal EP receptor 
(Figures 4.5, 4.6 and 4.11) was a surprise. This drug is a well characterized 
EP2  agonist (Nials et al, 1993). However, I am unaware of any previous 
study that has looked for EP antagonist effects of this drug. A selective 
EP 4  agonist would help in establishing the nature of the dilator EP 
receptors in rabbit ductus arteriosus, but no such drug has yet been 
described.
It may be that the antagonism of PGE2  by AH13205 points to an 
involvement of EP2  receptors, with AH13205 acting as a partial agonist, 
but this is unlikely. The fact that the absolute potency of PGE2  on the 
ductus is high indicates efficient receptor coupling, but AH13205 exhibits 
little agonist activity, whereas in preparations with substantially poorer 
coupling e.g. guinea pig trachea, where PGE2  is approximately 1 0 0 0 -fold 
weaker than on the ductus, AH13205 exhibits full agonist activity (Nials 
et al, 1993). Secondly, AH23848B has previously been shown to be 
without antagonist activity at EP2  receptors (Coleman et al, 1994a).
It has been known for some time that the ductus relaxes to PGI2  in high 
concentrations (Clyman et al, 1978c; Coceani et al, 1978b). However,
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therehavebeen no data to indicate whether this effect is mediated by an IP 
receptor, or whether it is a non-specific effect of PGI2  at the dilator EP 
receptor (it is characteristic of the native prostaglandins that, at high 
concentrations, they will act as agonists at receptors for other prostanoids 
[Coleman et al, 1990]). Relaxation of the ductus by the selective IP 
agonist, cicaprost (Sturzebecher et al, 1987; Armstrong et al, 1989), 
indicates that the ductus has IP receptors. This is supported by the fact 
that the selective antagonists of the ductal EP receptor, AH13205 and 
AH23848B, had little or no effect on the vessel's response to cicaprost 
(Figures 4.9 and 4.11). It is concluded that in addition to EP4  receptors, the 
fetal rabbit ductus arteriosus also has inhibitory IP receptors.
It has been reported previously that cicaprost is either equipotent with 
PGI2  at IP receptors or slightly more potent (Sturzebecher et al, 1987). 
The present finding that cicaprost is about 100-fold less potent than PGE2  
is, therefore, somewhat at odds with studies in the lamb, where the ductus 
was more than 1 0 0 0 -fold less sensitive to PGI2  compared with PGE2  
(Clyman et al, 1978c; Coceani et al, 1978b). While this may simply 
reflect a species difference, it is relevant that in the lamb ductus the 
response to PGI2  is slow, taking up to 1 2  minutes to plateau (Coceani et 
al, 1978b). Given that these authors noted that leaving PGI2  at room 
temperature for 30 minutes eliminated its activity on platelets, it is possible 
that at 37°C, PGI2  was broken down over the time course of the response 
of the ductus. This is not an important consideration with cicaprost which 
is considerably more stable than PGI2  (Sturzebecher et al, 1987).
Whatever the sensitivity of the ductus to PGI2  relative to PGE2 , the 
presence of an IP receptor on the ductus implies a role for PGI2  in the 
physiological control of the vessel. This is supported by the fact that PGI2  
is the main prostanoid formed by the ductus (see Chapter 1). Furthermore 
the absolute sensitivity of the ductus to cicaprost is compatible with other 
tissues under the physiological control of PGI2  (the EC5q for cicaprost on 
the rabbit ductus [27.8nM] is consistent with the EC5 0  described for the
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rabbit platelet of 22.2nM [Armstrong et al, 1989]).
Relaxation of the ductus by the selective DP receptor agonist, BW245C 
(Town et al, 1983; Whittle et al, 1983), taken in isolation, suggests that 
the the ductus has DP receptors (Figure 4.8). However, this is contradicted 
by a number of other observations. Firstly, BW245C was almost 900-fold 
weaker than PGE2  (Table 4.1); secondly, both AH23848B and AH13205 
were at least as effective in antagonizing BW245C as they were PGE2  
(Figures 4.10 and 4.12, respectively); and, thirdly, the potent DP receptor 
antagonist, BW8 6 8 C, had no significant effect on the sensitivity to 
BW245C at a concentration more than 1000 times its pA2  in other tissues 
(Giles et al, 1989). Taken as a whole, these data suggest that the dilator 
effect of BW245C is due to an action on the ductal EP receptor. This 
implies that the ductus does not have DP receptors and that the selectivity 
of BW245C for DP receptors is only relative, being an agonist at the ductal 
EP receptor albeit almost 900 times less potent than PGE2  itself.
These data may have real clinical relevance, but clearly, this depends on 
the similarity in the prostanoid receptor populations in the human and 
rabbit ductus arteriosus. The use of intra-venous PGEj to dilate the ductus 
in various forms of congenital heart disease in the human neonate is 
associated with common, serious adverse effects (see Gersony, 1986): 
seizures, apnoea (10-15%), hyperpyrexia (10-15%), diarrhoea and flushing 
(10%). Although information as to the prostanoid receptors mediating 
these effects is not available, it is likely that at least some of these adverse 
effects are mediated by different EP receptor sub-types from that mediating 
relaxation of the ductus. Thus, a selective agonist of the ductal EP receptor 
could have a significantly improved side effect profile compared with 
PGEj. The observation that the ductus has an IP receptor suggests the 
possibility of the use of PGI2  in treatment of ductus-dependent circulation, 
but this would probably be associated with other marked cardiovascular 
activity.
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These data may also have relevance to the treatment of PDA. If PGE2  is the 
predominant prostaglandin in the maintenance of ductal patency 
(Clyman, 1987; Coceani and Olley, 1988) and its effects are mediated 
through EP4  receptors, as the present work on rabbit ductus suggests, then 
an EP4  receptor antagonist should be equally effective as indomethacin 
but without many (or even any) of its adverse effects. And finally, these 
data have relevance to the the use of indomethacin as a uterine tocolytic. 
The contractile receptors for PGE2  in the human uterus are EPj and EP3  
(Senior et al, 1991). On the basis of this work, selective antagonists of 
these receptors would not be expected to contract the ductus.
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C h a p ter  5. In te r a c tio n s  b etw een  in d o m eth a c in , 
noradrenaline and vasodilators in the ductus arteriosus.
In my first study on the ductus, I demonstrated that indomethacin 
increased the sensitivity of the vessel to noradrenaline (Smith and 
McGrath, 1988), implying that an endogenous cyclo-oxygenase product 
(probably PGE2) inhibited the vessel's response to noradrenaline. One aim 
of the present study was, therefore, to establish whether exogenous PGE2  
inhibited the sensitivity of the vessel to noradrenaline.
I also wished to characterise the effect of indomethacin on the vessel's 
response to PGE2  and other vasodilators. Virtually every study on the 
effects of PGE2  on the ductus has used indomethacin to pre-contract the 
vessel and every comparison of the relative potency of prostanoids in 
dilating the ductus that I am aware of has used indomethacin to pre­
contract the ductus, both in vitro and in vivo (see Chapter 1). It has been 
demonstrated that indomethacin increased the sensitivity of the ductus to 
the dilator effect of PGE2  in high oxygen tension, but not low oxygen 
tension (Coceani et al, 1975). These authors concluded that indomethacin 
had an effect on the "target-site" for PGE2  on the ductus (presumably 
meaning either at the receptor or second-messenger system for PGE2).
If indomethacin increases the sensitivity of the ductus to PGE2, but not 
other prostanoids, the use of indomethacin to pre-contract the ductus in 
studies looking at the relative potencies of dilators might exaggerate the 
potency of PGE2  relative to other vasodilators. Furthermore, there are 
major flaws in the proposed explanation for the effect of indomethacin on 
the vessel's response to PGE2  (see section 5.3). In the following work I set 
out to characterise the effect of indomethacin on the vessel's response to a 
number of dilators and constructed experiments to elucidate the 
mechanism of the effect of indomethacin.
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5.1 Methods.
The general methods outlined in Chapter 2 were employed. All 
experiments described in this chapter were carried out in 15% oxygen, 
which resulted in an oxygen tension of 100-1 lOmmHg. Different protocols 
were used for eliciting contraction and relaxation responses, as outlined 
below.
5.1.1 Effects of PGE2  on response to noradrenaline.
The vessel was stretched to 0.2g.tension when set up, incubated for 90 
minutes before the addition of indomethacin, and the PSS was changed at 
30 and 60 minutes. Although the degree of stretch was slightly sub- 
optimal for contractile responses of the vessel in the presence of 
indomethacin, higher degrees of stretch resulted in greater variation in the 
sensitivity to noradrenaline over the course of the experiment (see Chapter 
3). Where indomethacin was used, the vessel was incubated in a 
concentration of lfiM of the drug for at least 30 minutes prior to addition 
of PGE2. Where the drug was not used, an identical time protocol was 
employed. The vessel was exposed to a given concentration of PGE2  for 
1 0  minutes prior to addition of noradrenaline.
Concentration contraction response curves (CCRC) to noradrenaline were 
obtained cumulatively. The response at a given concentration was allowed 
to reach a plateau prior to obtaining the next. The PSS was changed at 
least 3 times after each CCRC. A period of at least 45 minutes was allowed 
between CCRC and no more than 5 were obtained from each vessel.
5.1.2 Concentration relaxation response curves.
The vessel was stretched to 0.6g.tension initially and re-set at 60 minutes. 
The PSS was changed at 30 and 60 minutes and the vessel was incubated 
for 90 minutes before the addition of any drugs. After the vessel had been 
incubated in lpM propranolol (with or without lpM indomethacin) for 30
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minutes, to eliminate any effects of noradrenaline mediated through P- 
adrenoceptors, it was contracted with 10pM noradrenaline. The 
contraction was stable (after an initial peak) and was sustained for at least 
80 minutes. Concentration relaxation response curves (CRRC) to a given 
vasodilator were obtained cumulatively and commenced 2 0  minutes after 
addition of noradrenaline. The effect of a given concentration of drug was 
allowed to reach a maximum before addition of the next. The PSS was 
changed at least 4 times after a CRRC and at least 1 hour was allowed 
between CRRC. The effect of indomethacin was elucidated by comparing 
the response in IjiM indomethacin (incubated for at least 30 minutes) with 
the response in the drug’s absence, comparing the responses of different 
vessels using identical time protocols.
5.1.3 Quantification of responses.
The sensitivity of the vessel to agonists (contractile or relaxant) was 
quantified by the pEC5 0  (see section 2.4). The magnitude of the relaxation 
at any given concentration of vasodilator and the maximum relaxant 
response (MRR) were expressed as a % of the maximum relaxation as 
determined by addition of lOOnM PGE2  and 30pM papaverine at the end 
of every CRRC, which resulted in loss of all active tone as indicated by a 
fall below baseline and no further response to lpM  forskolin. The 
maximum contractile response (MCR) of noradrenaline was expressed as 
the increase in tone above changes induced by indomethacin and PGE2.
Changes in response parameters to noradrenaline in a given concentration 
of PGE2  were expressed in relation to a control response. The second 
CCRC was always used as the control response (in view of the time 
control data, Figures 3.6 and 3.7), and CCRC 3-5 were obtained in a range 
of [PGE2]. In the absence of indomethacin, a control response was 
obtained and subsequent responses in the presence of exogenous PGE2  
were compared to it. In the presence of indomethacin (lp.M) a control 
response was obtained in InM PGE2  and subsequent responses in a given
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concentration of PGE2  were compared to it. Where the time controls (from 
Figures 3.6 and 3.7) indicated that the given response parameter was 
stable comparing CCRC 2 and subsequent CCRC, paired statistical 
comparison was made between the test and control responses. Where time 
controls indicated a spontaneous change in response parameter with time, 
un-paired statistical comparison was made between the extent of change 
between the test and control response and the extent of change in the time 
controls.
5.2 Results.
In the presence of lpM  indomethacin, PGE2  from 0.01 nM to lOOnM 
decreased the pEC5 0  to noradrenaline covering a range of 2.39 log units 
(i.e. a 245 fold increase in EC5 0  [M] to noradrenaline, Figure 5.1). The 
relationship between [PGE2] and the MCR (% control maximum) to 
noradrenaline was bell-shaped. Concentrations of 0.03nM and below and 
30nM and above were associated with a decreased MCR compared with 
the MCR in InM PGE2  (Figure 5.2).
In the absence of indomethacin, PGE2  of InM and above decreased the 
pEC5 0  to noradrenaline compared with control (Figure 5.3). The maximum 
decrease in pEC5 0  from control and correcting for the effect of time was 
between 0.4 to 0.5 log units (i.e an approximately 3 fold increase in the 
EC5 0  [M]). Addition of PGE2  between O.lnM and lOnM increased the 
MCR (% control maximum) to noradrenaline, whereas lOOnM PGE2  
decreased it (Figure 5.4).
By comparing the plot of the raw data for the relationship between [PGE2] 
and pEC5 0  to noradrenaline in the presence of indomethacin with the 95% 
confidence intervals for the control pEC5 0  to noradrenaline in the absence 
of indomethacin, the effect of endogenous prostaglandins on the response 
of the vessel to noradrenaline was estimated as being equal to a bath 
concentration of approximately InM PGE2  with indomethacin present
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(Figure 5.5).
With the ductus pre-contracted with 10|iM noradrenaline the response to 
PGE 2  was virtually the same in the presence and absence of lpM  
indomethacin (Figure 5.6). A representative trace of the response to PGE2  
with the vessel pre-contracted with 10|xM noradrenaline in lpM  
indomethacin in 15% oxygen is given in Figure 6.12.A.
The response of the ductus to a range of vasodilators was elucidated in the 
presence and absence of indomethacin, the vessel pre-contracted with 
lOpM noradrenaline. Indomethacin decreased the pEC5 0  to cicaprost but 
increased its MRR (Figure 5.7); decreased the pEC5 0  and MRR to 
cromakalim (Figure 5.8); and decreased the pEC5 0  to forskolin, but had no 
effect on the MRR (Figure 5.9). There was no significant difference in the 
amount of active tone present with lOpM noradrenaline comparing the 
presence and absence of indomethacin (mean in mN [SEM]: 13.0 [0.52], 
n=28 vs 13.5 [0.56], n=28, respectively, p=0.55).
Addition of 0.3nM PGE2  partially reversed the effect of indomethacin on 
the sensitivity of the ductus to forskolin (Figure 5.10).
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Figure 5.1 The effect of PGE2  on the pEC 5 0  to noradrenaline in the 
presence of lpM  indomethacin. A control response was obtained in InM 
PGE2  (CCRC 2, same time protocol as Figure 3.7). The pEC5 0  (-log1 0  M) of 
the control response was subtracted from the pEC5 0  of the response in a 
given [PGE2] and the difference is plotted on the y axis. The range of 
change in pEC5 0  across the range of [PGE2] is 2.39. Points are means, bars 
are SEM (each point, n=8-14).
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Figure 5.2 The effect of PGE2  on the maximum contractile response 
(MCR) to noradrenaline in the presence of lpM  indomethacin. A
control response was obtained in InM PGE2  (CCRC 2, same time protocol 
as Figure 3.7). The MCR in the presence of a given concentration of PGE2  
is expressed as a percentage of the control MCR of CCRC 2. Student's 
paired t test was used to compare the test and control response *p<0.05, 
**p<0.01. Points are means, bars are SEM (each point n=8-14).
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Figure 5.3 The effect of PGE2  on the pEC 5 0  to noradrenaline in the 
absence of indomethacin. The pEC5 0  (-log1 0  M) of the control response 
(CCRC 2 , same time protocol as Figure 3.6) was subtracted from the pEC5 0  
of the response in a given [PGE2] and the difference is plotted on the y 
axis. The difference was compared with the mean difference in pEC5 0  of 
time controls (-0.169 [SEM 0.036], see Figure 3.6) which is indicated on 
the graph by the broken line. Student's t-test *p<0.05 **p<0.01. Points are 
means, bars are SEM (each point n=7-12).
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Figure 5.4 The effect of PGE2  on the maximum contractile response 
(MCR) to noradrenaline in the absence of indomethacin. The MCR in
the presence of a given [PGE2] is expressed as a % of the MCR of the 
control response (CCRC 2, same time protocol as Figure 3.6). Student's 
paired t test was used to compare the test and control response *p<0.05, 
**p<0.01. Points are means, bars are SEM (each point n=7-12).
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Figure 5.5 The control pEC 5 0  (-log1 0  M) to noradrenaline (NA) 
compared with the pEC5 0  in lfiM indomethacin in the presence of 0.01 
to lOOnM PGE2. This graph presents the raw data from Figure 5.1, all 
responses CCRC 3 to 5. The dotted lines from the y-axis represent the 
95% confidence intervals of the pEC5 0  to noradrenaline in the absence of 
indomethacin and PGE2  (7.01 to 7.34, n=32: this data is from the control 
response, CCRC 2, from Figure 5.3). Points are means, bars are SEM (each 
point, n=8-14).
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Figure 5.6 The effect of indomethacin (lfxM) on the response to PGE2  
in lOpM noradrenaline. lpM  indomethacin ( • )  and control (O ). 
Comparing the responses to PGE2 , there was no significant difference in 
either pEC^C-log^ M; mean [SEM]: 8.71 [0.16], n=8 , vs 8.50 [0.10], n=8 , 
respectively, p=0.30) or maximum relaxant response (% maximum 
relaxation, 76.1 [5.6] vs 74.5 [5.5], respectively, p=0.39). Student’s t test. 
Points are means, bars are SEM.
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Figure 5.7 The effect of indomethacin (lpM ) on the response to 
cicaprost in 10pM noradrenaline. lpM indomethacin (# )  and control 
(O). The pEC5 0  (-log1 0  M) to cicaprost was significantly lower in lpM 
indomethacin compared with control (mean [SEM]: 6.78 [0.10], n=8 , vs 
7.20 [0.07], n=8 , respectively, p=0.0053) whereas the maximum relaxant 
response (% maximum relaxation) was significantly elevated in 
indomethacin (8 8 . 8  [1.6] vs 81.3 [2.5], respectively, p=0.028). Student's t 
test. Points are means, bars are SEM.
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Figure 5.8 The effect of indomethacin (l|xM) on the response to 
cromakalim in 10|xM noradrenaline. lpM indomethacin ( • )  and control 
(O). The pEC5 0  (-log1 0  M) to cromakalim was lower in lpM indomethacin 
compared with control (mean [SEM]: 6.75 [0.04], n=4 vs 7.30 [0.03], n=4, 
respectively, p=0 .0 0 0 1 ) as was the maximum relaxant response (% 
maximum relaxation, 39.2 [1.5] vs 59.8 [6.9], respectively, p=0.061). 
Student's t test. Points are means, bars are SEM.
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Figure 5.9 The effect of indomethacin (l|xM) on the response to 
forskolin in 10)xM noradrenaline. l|xM indomethacin (# )  and control 
(O). The pEC5 0  (-logio t 0  f°rskolin was significantly lower in lpM 
indomethacin compared with control (mean [SEM]: 6.43 [0.07], n=8 , vs 
7.25 [0.08], n=8 , respectively, p<0.0001). Student's t test. Points are means, 
bars are SEM. Note- forskolin caused complete relaxation both in the 
presence and absence of indomethacin.
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Figure 5.10 Partial reversal of the effect of indomethacin (ljiM) on 
response to forskolin by PGE2. Control response in absence of 
indomethacin and PGE2  (O , n=8 ). Subsequent response in lpM  
indomethacin ( • ,  n=4) and lfiM indomethacin + 0.3nM PGE2  (■, n=4). 
The change in pEC5 0  (-log1 0  M) from the control response was 
significantly less in the presence of 0.3nM PGE2  than in its absence (-0.47 
[0.06] vs -0.78 [0.09], respectively, p=0.034, Student's t-test). Points are 
means, bars are SEM.
98
5.3 Discussion.
In a previous study on the neonatal rabbit ductus arteriosus, I 
demonstrated increased sensitivity of the vessel to noradrenaline following 
incubation in indomethacin, implying that prostaglandins synthesised by 
the ductus inhibit its response to noradrenaline (Smith and McGrath, 
1988). The present study demonstrated that PGE2  is a potent functional 
antagonist of noradrenaline in the ductus arteriosus. Figure 5.1 reveals that 
inhibition of ductal sensitivity to noradrenaline is almost maximal by a 
PGE2  concentration of 3nM, at which ductal sensitivity to noradrenaline is 
reduced by about 240 times. Since the concentration of PGE2  in fetal 
arterial blood is about l-2nM (Clyman et al, 1980c), it is probable that this 
action of PGE2  is of importance in the physiological control of the vessel.
Another aim of this study was to elucidate whether indomethacin has an 
effect on the sensitivity of the PGE2  receptor-effector system. The 
evidence which suggests that it does is work by Coceani et al, (1975) 
which demonstrated an increased response to PGE2  following incubation 
in indomethacin in the presence of elevated, but not low, oxygen tension. 
The ductus synthesises its own prostaglandins (see Chapter 1) which relax 
the vessel, as evidenced by the contraction induced by indomethacin 
(Coceani et al, 1975). The effects of indomethacin on the ductus are 
thought to be mediated entirely by elimination of PGE2  (Clyman, 1987; 
Coceani and Olley, 1988). In the absence of indomethacin, therefore, the 
effect of exogenous PGE2  will be super-imposed on the effects of PGE2  
produced in the vessel wall. It follows that exogenous PGE2  will only 
begin to have an effect when it significantly exceeds the concentration of 
endogenous PGE2  to which the vessel is exposed. Where a tissue 
produces a sufficient concentration of prostaglandin to have a biological 
effect, indomethacin will cause an apparent increase in the tissue's 
response by removing the contribution of endogenous prostaglandins. 
Coceani and colleagues (1975) did not consider this explanation for their
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results. I wanted to test the hypothesis that the effect of indomethacin on 
the sensitivity of the ductus arteriosus to PGE2  could be explained by 
elimination of the effect of endogenous PGE2 .
I tested the hypothesis in two ways. Firstly I looked at the effect of PGE2  
on the pEC5 0  to noradrenaline, in the presence and absence of 
indomethacin. Treatment with indomethacin increases the pEC5 0  of the 
ductus to noradrenaline (Smith and McGrath, 1988) and PGE2  decreases it 
(Figure 5.1). It is unaffected by changes in ductal smooth muscle tone per 
se (Smith and McGrath, 1988). It acts as a useful index, therefore, of the 
effects of endogenous and exogenous PGE2. The second approach was to 
look at the dilator effects of PGE2, with and without indomethacin, in the 
presence of a very high level of tone which exceeded the inhibitory effects 
of endogenous PGE2. For this the ductus was pre-contracted with 10pM 
noradrenaline.
Looking at the data on the effect of a range of [PGE2] on the pEC5 0  to 
noradrenaline in the presence and absence of indomethacin, they appear to 
confirm that indomethacin increases ductal sensitivity to PGE2. In the 
absence of indomethacin, PGE2  (from InM to lOOnM) decreased the 
pEC 5 0  to noradrenaline to a maximum of 0.4 to 0.5 log units (i.e. an 
approximately 3 fold increase in EC5 0  [M], Figure 5.3). In the presence of 
lpM  indomethacin, PGE2, across the range O.OlnM to lOOnM, decreased 
the pEC5 0  to noradrenaline by 2.39 log units (i.e. a 245 fold increase in 
EC5 0  Figure 5.1).
Figure 5.5 illustrates the relationship between [PGE2] and pEC5 0  to 
noradrenaline. By superimposing the 95% confidence intervals of the 
control pEC5 0  to noradrenaline on this graph, it is clear that in the absence 
of indomethacin endogenous PGE2  had a profound inhibitory effect on 
the vessel's pEC5 0  to noradrenaline. Indeed, a rough estimation of the 
effects of endogenous PGE2  can be made in terms of equivalence to a bath
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[PGE2 ] with indomethacin present, which I estimate to be in the region of 
InM. In the absence of indomethacin, PGE2  had an effect on the pEC5 0  to 
noradrenaline only at concentrations of InM and above. Taking these data 
together I conclude that the major effect, possibly exclusive effect of 
indomethacin to increase the sensitivity of the ductus to the effects of 
PGE2  is explained by elimination of endogenous PGE2 .
This hypothesis was further tested by raising tone with 10|iM 
noradrenaline and obtaining a CRRC to PGE2. The absence of a major 
inhibitory effect of endogenous PGE2  is indicated by the fact that the 
extent of pre-contraction was the same in the presence and absence of 
indomethacin. Under these circumstances, indomethacin had no effect on 
the sensitivity or MRR to PGE2  (Figure 5.6), which provided further 
support for this model of the effect of indomethacin.
This hypothesis predicts that the effects of indomethacin on the sensitivity 
of the ductus will be increased in situations where endogenous PGE2  
synthesis is stimulated. Elevated oxygen tension massively stimulates 
ductal synthesis of PGE2  (Clyman et al, 1980b). Coceani et al, (1975), 
looking at similar changes in oxygen tension, found that indomethacin 
only increased sensitivity to PGE2  in elevated oxygen tension. I conclude, 
therefore, that indomethacin potentiates the response to PGE2  primarily by 
eliminating the effects of endogenous PGE2. Any study of the effects of 
prostaglandin synthesis inhibitors on the response of the ductus to 
exogenous prostaglandins will have to take this effect into account before 
postulating effects on the PGE2  receptor-effector mechanism.
Both in the presence and absence of indomethacin, PGE2  had complex 
effects on the MCR (% control maximum) to noradrenaline. With 
indomethacin present (Figure 5.2), low concentrations of PGE2  (<0.03nM) 
were associated with a decreased MCR to noradrenaline. This was 
probably due to the fact that the noradrenaline and indomethacin 
contractions are not additive (as indicated by the fact that the active tone
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present in 10pM noradrenaline was the same in the presence and absence 
of lpM indomethacin). By eliminating some of the indomethacin-induced 
tone, moderate concentrations of PGE2  (0.1 to lOnM) actually increased 
the MCR to noradrenaline. This effect was overcome by a direct inhibitory 
effect on the response to noradrenaline of higher concentrations of PGE2  
(>30nM). The effects of PGE2  on the MCR to noradrenaline in the 
absence of indomethacin (Figure 5.2) were more difficult to explain. PGE2  
caused a small, but significant increase in MCR across the range 0.1 to 
lOnM. This may have been due, again, to elimination of tone. Alternatively, 
I have some evidence for the existence of a contractile receptor for PGE2  
on the ductus (see Chapter 7) which might explain this stimulatory effect. 
Whatever the mechanism, this effect was overcome by a direct inhibitory 
action in high concentrations of PGE2.
While indomethacin had no effect on the response of the ductus to PGE2  
in the presence of lOfxM noradrenaline, it did have effects on the response 
of the ductus to other vasodilators (Figures 5.7 to 5.9). In the absence of 
indomethacin, the sensitivity of the ductus to cicaprost (a stable PGI2  
mimetic [Armstrong et al, 1989]), forskolin (a direct activator of adenylate 
cyclase [Seamon and Daly, 1981]) and cromakalim (an activator of ATP- 
sensitive potassium channels [Bray et al, 1991]) was increased. This was 
probably due to synergy between these exogenous dilators and 
endogenous PGE2. I tested this hypothesis by comparing the effect of 
indomethacin on the response to forskolin in the presence and absence of 
0.3nM PGE2  (Figure 5.10). Addition of this small concentration of PGE2  
reversed somewhat the effect of indomethacin. I conclude, therefore, that 
the ductus was more sensitive to exogenous vasodilators, other than PGE2, 
in the absence of indomethacin and that this was due to a potentiating 
effect of endogenous PGE2.
Converting the data in Figures 5.6 and 5.7 into molar concentrations, 
PGE2  was about 85 times more potent than cicaprost in the presence of
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indomethacin but only 2 0  times more potent than cicaprost in its absence. 
The greater the contribution of endogenous PGE2, the more potent 
cicaprost will become when compared with PGE2  since ( 1 ) endogenous 
PGE2  will increase the vessel's sensitivity to cicaprost; and, (2) endogenous 
PGE2  will decrease the vessel's sensitivity to exogenous PGE2. The above 
experiments used 10|iM noradrenaline to minimise the effects of 
endogenous PGE2. The potency of cicaprost compared with PGE2  in the 
absence of indomethacin may be increased in situations of lesser 
constriction of ductal smooth muscle, as the contribution of endogenous 
PGE2  will further decrease the vessel's response to exogenous PGE2. 
Furthermore, given that the ductus is also exposed to circulating PGE2  in 
vivo (indeed it has been suggested that this is the major source of PGE2  to 
which the vessel is exposed [Clyman et al, 1980b]) this suggests that 
cicaprost may even more potent relative to PGE2  in vivo than in the 
present study.
Previous comparisons of the relative potency of different prostaglandins as 
dilators of the ductus, both in vitro (Clyman et al, 1978a and 1978c; 
Coceani et al, 1978b) and in vivo (Friedman et al, 1983) have been in 
the presence of indomethacin and it was on the basis of these studies that 
PGEj was selected to be used to maintain artificially ductal patency in 
neonates with ductus-dependent circulation. It seems likely, therefore, that 
comparing the effects of different prostaglandins in the presence of 
indomethacin as a guide to their potency in the human infant with ductus- 
dependent circulation has led to two sources of error: ( 1 ) the sensitivity of 
the vessel to PGEj was overestimated as the effects of endogenous PGE2  
had been eliminated; and, (2) the sensitivity of the vessel to PGI2  was 
underestimated, due to the absence of its potentiation by endogenous 
PGE2. The extent of this "error" will depend on the concentration of 
endogenous PGE2  to which the smooth muscle of the ductus is exposed 
in vivo. I propose that the relative potencies of ductal vasodilators need 
to be re-evaluated in better models of the physiological and clinical states.
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The effect of indomethacin on the MRR (% maximum relaxation) to 
dilators was less straightforward. Indomethacin increased the MRR to 
cicaprost, decreased the MRR to cromakalim and had no effect on the 
MRR to forskolin (Figures 5.7 to 5.9). The MRR to forskolin was 
unchanged by indomethacin as it caused complete relaxation whether 
endogenous PGE2  was present or not. The decrease in MRR to 
cromakalim in the presence of indomethacin was probably due to loss of 
synergy with endogenous PGE2. Endogenous PGE2  potentiated the 
sensitivity to cicaprost (as indicated by the effect of indomethacin). If it 
had also potentiated its MRR, indomethacin would have decreased rather 
than increased the MRR to cicaprost. The effect of indomethacin on the 
MRR to cicaprost cannot, therefore, be explained by eliminating the 
effects of endogenous PGE2, but it could be explained by the elimination 
of endogenous PGI2. PGI2  is the main prostanoid formed by the ductus 
(see Chapter 1). If endogenous PGI2  inhibited the contraction to lOpM 
noradrenaline, indomethacin would be expected to increase the maximum 
relaxation to a PGI2  mimetic by a similar reasoning as developed above for 
the effect of indomethacin on the response to PGE2.
In summary, indomethacin increased the sensitivity of the ductus arteriosus 
to PGE2, decreased its sensitivity to cicaprost, cromakalim and forskolin, 
and decreased its maximum response to cromakalim. All these effects can 
be explained in terms of eliminating endogenous PGE2. In addition, 
indomethacin increased the maximum response to cicaprost, which could 
be explained by elimination of endogenous PGI2, but not PGE2.
104
C hapter 6. In tera ctio n s b etw een  oxygen  ten sio n , 
noradrenaline and vasodilators in the ductus arteriosus.
It had been demonstrated that oxygen tension inhibits the sensitivity of 
the ductus arteriosus to PGE2  in the absence but not the presence of 
indomethacin (Coceani et al, 1975). As discussed in some detail in the 
preceding chapter, these authors concluded that indomethacin altered the 
sensitivity of the "target-site" for PGE2, and that the drug reversed the 
inhibitory effect of elevated oxygen tension. In the preceding chapter, it 
was demonstrated that this was almost certainly a spurious conclusion and 
that the observed effects of oxygen tension and indomethacin could be 
explained in terms of their effect on endogenous PGE2  production which 
would alter the vessel’s response to exogenous PGE2. Nevertheless, given 
that PGE2  is central to keeping the ductus patent in the fetus, and that 
oxygen is central to closing the vessel in the neonate, it might be expected 
that some interaction exists between the vessel's sensitivity to PGE2  and 
the prevailing oxygen tension. In this part of the work, I set out to test the 
hypothesis that PGE2  and oxygen interact.
In this chapter, I describe (1) the effect of oxygen tension on the inhibitory 
actions of PGE2  on the response of the ductus to noradrenaline; (2) the 
effect of oxygen tension on the response of the ductus to PGE2  and other 
vasodilators, prostanoid and non-prostanoid, with the vessel pre­
contracted with lOpM noradrenaline. These experiments were carried out 
in the presence of lpM indomethacin to eliminate misleading effects due to 
changes in endogenous PGE2  production. In addition, experiments were 
carried out where indomethacin was omitted or substituted with a 
structurally unrelated cyclo-oxygenase inhibitor, flubriprofen.
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6.1 Methods.
The general methods outlined in Chapter 2 were employed. In this chapter, 
the amount of oxygen bubbling the preparations was manipulated to 
elucidate the effect of oxygen tension on the response of the ductus to 
contractile and relaxant agonists.
6.1.1 Effects of PGE2  and oxygen on response to noradrenaline.
These experiments (data in Figures 6.1 to 6.4) were conducted on different 
equipment from all the rest of the experimental work described in this 
thesis, although the animals used and general experimental design were 
identical. The amplification and chart recorder system was a polygraph 
chart recorder (Grass, model 7PCPA). The organ baths were of a special 
design, being deep with a narrow top, to reduce diffusion of atmospheric 
oxygen. The proportion of oxygen used in the gas bubbling system was 
slightly different, therefore, to that described in section 6 .1 .2 , although the 
actual oxygen tensions obtained were similar.
When mounted, the vessels were stretched to 0.2g.tension, which was not 
re-set. Although the degree of stretch was slightly sub-optimal for 
contractile responses of the vessel in the presence of indomethacin, higher 
degrees of stretch resulted in greater variation in the sensitivity to 
noradrenaline over the course of the experiment (see Chapter 3). 
Following mounting, the vessels were allowed to equilibrate for 90 
minutes. The PSS was changed at 30 and 60 minutes. The bath was 
bubbled with 3,10,15, or 95% O2 ; 5% CO2 ; and remainder N2 . The above 
procedure yielded a bath P 0 2  (in mmHg) of 27.2 (SEM 1.7) with 3% 
oxygen, 75.4 (SEM 0.8) with 10% oxygen, and 107.0 (SEM 0.8) with 15% 
oxygen. Vessels were equilibrated in a given P 0 2  for a minimum of 45 
minutes before a concentration contraction response curve (CCRC) was 
obtained. All experiments were carried out in the presence of lpM  
indomethacin, added at least 30 minutes prior to the addition of PGE2.
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PGE2  was added to the bath 1 0  minutes prior to eliciting any response.
CCRC to noradrenaline were obtained cumulatively. The response at a 
given concentration was allowed to reach a plateau prior to obtaining the 
next. The PSS was changed at least 3 times after each CCRC. A period of 
at least 45 minutes was allowed between CCRC and no more than 5 were 
obtained from each vessel. Contractions due to potassium-induced 
depolarisation were obtained by addition of molar KC1 to the organ bath. 
When the response to potassium was elicited, the response in lOnM PGE2  
was obtained first and the response in 0.0InM PGE2  obtained second.
6.1.2 Effects of oxygen on vasodilators
The equipment was used in these experiments was the same as in the rest 
of the work described in this thesis, with the exception of Figures 6.1 to 
6.4.
The vessel was stretched to 0.6g.tension which was re-set 60 minutes later. 
The PSS was changed at 30 and 60 minutes following mounting and the 
vessels were allowed to incubate for 90 minutes in 15% oxygen prior to 
addition of indomethacin. The baths were bubbled with gas mixtures of 2 
or 15% 0 2, 5% C 02, and remainder N2 . When 2% 0 2  was used, the organ 
bath was partially covered with chemically inert film to reduce diffusion of 
oxygen from the air. Bubbling with 2% 0 2  resulted in a P 0 2  of 19- 
23mmHg, which is consistent with the fetal oxygen tension to which the 
ductus is exposed (Heymann and Rudolph, 1975) and bubbling with 15% 
0 2  resulted in a P0 2  of 100-1 lOmmHg. Vessels were equilibrated in a given 
P 0 2  for a minimum of 45 minutes before a concentration relaxation 
response curve (CRRC) was obtained.
The vessel was pre-contracted with 10pM noradrenaline. The 
noradrenaline contraction was stable and time controls demonstrated that 
it was sustained for at least 80 minutes. Prior to addition of noradrenaline
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the vessel was incubated in lpM propranolol for 30 minutes, to eliminate 
any effects of noradrenaline mediated through (3-adrenoreceptors. Unless 
otherwise stated, experiments were carried out in the presence of l|xM 
indomethacin. When it was omitted or substituted by flubriprofen, it is 
stated in the text and figure legend. Indomethacin (l|xM) or flubriprofen 
(lpM ) were added with the propranolol, as appropriate (the two cyclo- 
oxygenase inhibitors are roughly equipotent in human umbilical artery 
[MacLennan et al, 1988]). In experiments where neither cyclo-oxygenase 
inhibitor was used, the same time protocol was employed.
The cumulative CRRC to the given agonist was commenced 20 minutes 
after addition of noradrenaline. The effect of a given concentration of drug 
was allowed to reach a maximum before addition of the next. In all cases 
the first CRRC was in 15% oxygen. The effects of oxygen tension were 
elucidated by obtaining a second response in 2% oxygen. To correct for 
any effect of time, controls were obtained where both the first and second 
responses were in 15% oxygen. No separate time controls were obtained 
for responses to PGE2  in flubriprofen and in the absence of a cyclo- 
oxygenase inhibitor. Instead, a third CRRC was obtained in 15% oxygen 
which, by comparison with the first CRRC in 15% oxygen, confirmed that 
the response to PGE2  under these conditions was stable with time. The 
PSS was changed at least 4 times after an CRRC and at least 1 hour was 
allowed between CRRC.
6.1.3 Quantification of responses.
The sensitivity of the vessel of agonists (contractile or relaxant) was 
estimated by the pEC5 0  (see section 2.4 for definition). The sensitivity of 
the vessel to the dilator effect of cicaprost, forskolin and PGE2  was also 
quantified by an index which was relative to the size of pre-contraction: 
the pEC30*, where the EC30* is the interpolated molar concentration of the 
agonist which caused a reduction in tone of 30% of the extent of pre­
contraction under the given conditions. The asterix is used to emphasize 
the difference between the method of calculating this and the EC50.
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For noradrenaline, only data from CCRC 2-5 were used for comparison of 
pEC5 0 s, given the time controls of Figure 3.7. However, data from any 
CCRC wereused for comparison of maximum responses to noradrenaline as 
this was unaffected over the course of time under these conditions (see 
section 3.2). The maximum contractile response (MCR) to noradrenaline in 
10% and 3% oxygen was expressed as a proportion of the same vessel's 
MCR to noradrenaline in 95% oxygen.
The magnitude of the relaxation at any given concentration and the 
maximum relaxant response (MRR) were expressed as a % of the maximum 
relaxation as determined by addition of lOOnM PGE2  and 30p,M 
papaverine at the end of every CRRC, which resulted in loss of all active 
tone (i.e. below baseline and with no further response to lpM forskolin).
6.2 Results.
6 .2 . 1  Effects of PGE2  and oxygen on response to noradrenaline.
In the presence of lpM indomethacin and InM PGE2, decreasing oxygen 
decreased the pEC5 0  and maximum response to noradrenaline (Figure 6.1). 
This effect of oxygen was completely reversible as illustrated by the 
original tracings in Figure 6.2. The maximum response to noradrenaline in 
0.01 nM PGE2  was the same in 95% and 3% oxygen, and the effect of 
oxygen on the maximum response of the vessel to noradrenaline was 
dependent on the presence of PGE2  in a concentration-dependent manner 
(Figure 6.3)
In the presence of 15% oxygen and l|xM indomethacin, increasing PGE2  
from 0.01 nM to lOnM decreased the vessel's sensitivity and maximum 
response to potassium-induced contraction of the ductus (Figure 6.4).
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6.2.2 Effects of oxygen on vasodilators.
With the vessel pre-contracted with IOjiM noradrenaline in lpM  
indomethacin and 15% oxygen (pooling the first responses in 15% 
oxygen), the rank order of MRR of agonists was: forskolin > cicaprost > 
PGE2  »  cromakalim »  adenosine ~ SNP > ANP = nifedipine = 0 (Figure 
6.5). Only for the first four of these was the response sufficient to calculate 
a pEC50. The rank order of pEC5 0  (-log1 0 M) of these agonists was (mean 
[SEM]): PGE2  (8.65 [0.12] n=15) »  cicaprost (6.80 [0.06] n=15) * 
cromakalim (6.58 [0.06] n=16) * forskolin (6.42 [0.05] n=12); one way 
ANOVA of means: F ratio = 156.65, p<0.0001. Multiple comparisons 
revealed that the pEC5 0  for PGE2  greater than all other agonists, cicaprost 
was significantly greater than forskolin, but there were no other significant 
differences (see Appendix [Table A.6 ] for table of values of 95% Cl of 
pairwise differences). Converting these data into molar concentrations, 
PGE2  was about 70 times more potent than cicaprost.
Two agonists, nifedipine (up to 30pM) and atrial natriuretic peptide (up to 
lOOnM) had no significant dilator effect in either 15% or 2% oxygen 
tension. The MRRs of all the other agonists were potentiated in 2% 
oxygen (Figures 6 . 6  to 6.10) except forskolin, which caused complete 
relaxation in 15% oxygen (Figure 6.11). The effect of oxygen on the 
response to PGE2  is illustrated by original tracings (Figure 6.12). With 
some agonists, the initial response in 15% oxygen was so small that no 
pEC5 0  value could be obtained. All of the four agonists where a pEC5 0  
could be calculated (cicaprost, cromakalim, forskolin and PGE2) showed a 
significant increase in pEC5 0  in 2% compared with 15% oxygen (Table 
6.1).
The response in 2% oxygen was obtained after the response in 15% 
oxygen. Time controls for all agonists were obtained for two consecutive 
responses in 15% oxygen (Table 6.2). Comparing the two responses, there 
was no change in the response to forskolin, PGE2  or SNP. However, the
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pEC5o to cicaprost and cromakalim and the MRR to adenosine, cicaprost, 
and cromakalim were significantly increased at the second response 
compared to the first.
For agonists which showed a significant change in time controls, the 
extent of change with varying oxygen tension was compared with the 
extent of spontaneous change with time (Table 6.3). In every such case 
the effect of oxygen was significantly greater than the spontaneous 
change with time. After correcting the change in pEC5 0  going from 15% to 
2 % oxygen for the mean change in the time controls (cicaprost and 
cromakalim only), there was no significant difference in the extent of 
change in pEC5 0  between the four agonists; one way ANOVA of means: F 
ratio = 2.30, p=0.100.
The total extent of active tone prior to a CRRC was elucidated by 
obtaining complete relaxation at the end (see section 6.1.3). The active 
tone present prior to the first CRRC (i.e 15% oxygen, lpM  indomethacin 
and 10pM noradrenaline) was 11.6mN (SEM 0.3, n= 8 6 ). The amount of 
active tone prior to the CRRC in 2% oxygen was 99.8% (n=47; 95% Cl 
94.6 to 105.0) that of the preceding CRRC in 15% oxygen. However, the 
active tone prior to the second CRRC in 15% oxygen (i.e. the time 
controls) was 107.8% (n=39; 95% Cl 105.5 to 110.1) that of the preceding 
CRRC in 15% oxygen. The difference between the active tone present in 
2% oxygen and its time control in 15% oxygen although small, was 
statistically significant (p=0.0064, Student's t-test, 95% Cl of difference:
2.3 to 13.6).
The amount of tone resulting from the first addition of indomethacin was 
always greater than later on in the experiment: the active tone prior to 
addition of 10pM noradrenaline (data from the time controls in 15% 
oxygen) at CRRC 1 was 12.3mN (SEM 0.4, n= 39) and at CRRC 2 was 
5.5mN (SEM 0.6) (p<0.0001). The active tone prior to addition of 10|iM 
noradrenaline in 2% oxygen was 1.5mN (SEM 0.2, n=47) which was
I l l
significantly less than the second time control (jxO.OOOl).
For three agonists (cicaprost, forskolin and PGE2), the response in 15% 
oxygen was of sufficient magnitude to calculate a pEC30*, which corrects 
estimation of sensitivity for the magnitude of pre-contraction (see section
6.1.3). In all three cases the pEC30* was increased in 2% oxygen compared 
with 15% (Table 6.1). There was a spontaneous increase in pEC30* with 
time to cicaprost, but not the other two agonists (Table 6.2). The extent of 
change in pEC30* to cicaprost with oxygen was significantly greater than 
with time (Table 6.3). There was no significant difference in the extent of 
change in pEC30* with decreased oxygen tension (cicaprost corrected for 
time controls) between the three agonists; one way ANOVA of means: F 
ratio 1.15, p=0.337.
Oxygen still altered the PGE2  CRRC when indomethacin was omitted or 
when the vessel was incubated in lpM  flubriprofen instead of 
indomethacin (Figures 6.13 and 6.14, respectively). The magnitude of the 
effect of oxygen on the pEC5 0  was the same in indomethacin, flubriprofen 
or in the absence of these drugs (mean change [SEM]: 0.51 [0.12], n=7; 
0.56 [0.04], n=4; 0.53 [0.18], n=7, respectively, F ratio = 0.02, p=0.979). 
The MRR to PGE2  in 15% oxygen was also the same under the three sets 
of conditions (Figure 6.15). However, the MRR to PGE2  in 2% oxygen 
was decreased in the absence of a cyclo-oxygenase inhibitor compared 
with both indomethacin and flubriprofen (Figure 6.15).
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Figure 6.1 Response to noradrenaline in InM  PGE 2  and lpM  
indomethacin 95%, 10% and 3% oxygen. O  95% oxygen, n=7 A 10% 
oxygen, n=3; and, □  3% oxygen, n=7. Responses in 10% and 3% oxygen 
were paired with responses in 95% oxygen and contractile response in 
10% or 3% oxygen were expressed in relation to control response in 95% 
oxygen. The mean decrease in maximum response from 95% to 10% was 
28% (95% Cl 12 to 44, p=0.017); from 95% to 3% was 79% (95% Cl 6 8  
to 90, p<0.0001); and, from 10% to 3% was 6 6 % (95% Cl 30 to 102, 
p=0.016). The mean change in pEC5 0  (-log1 0 M) from 95% to 10% was 
0.30 (95% Cl -0.41 to 1.01, p= 0.22), from 95% to 3% was 0.46 (95% Cl 
0.10 to 0.82, p= 0.02) and from 10% to 3% was 0.40 (95% Cl 0.07 to 0.74, 
p=0.035). All comparisons Student’s paired t test. Points are means, bars 
are SEM.
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Figure 6.2 Original tracing of consecutive responses to noradrenaline 
in lpM  indomethacin and InM PGE2  in A. 95%, B. 3% and C. 95% 
oxygen. Original tracings of 3 consecutive concentration response curves 
to noradrenaline from a single vessel in InM PGE2  and lpM indomethacin. 
A-in 95% oxygen, B-in 3% oxygen, C-in 95% oxygen again. In the four 
vessel's studied, there was no significant difference between the two 
CCRC in 95% oxygen in terms of either sensitivity (pECso: 6.43 [0.11] vs 
6.26 [0.12] respectively, n=4, p>0.1) or maximum contractile response (649 
mg [85] vs 710 mg [113] respectively, n=4, p>0.1). Student's paired t-test.
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Figure 6.3 Synergy between PGE2  and oxygen tension to inhibit the 
maximum contractile response (MCR) to noradrenaline. On the Y axis 
is plotted the mean change in MCR to noradrenaline from a control 
response in 95% to a test response in 3% oxygen, each point is the mean 
of 3-7 different vessels, bars are SEM. The mean decrease from 95% to 3% 
(95% Cl and p value Student’s paired t test): 0.01 nM PGE2  -0.2% (-28 to 
28, p=0.98); O.lnM PGE2  23% (5 to 41, p=0.031); InM PGE2  79% ( 6 8  to 
90, pcO.0001); lOnM PGE2  82% (65 to 100, p=0.0007).
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Figure 6.4 The effect of increasing PGE2  from O.OlnM to lOnM on 
contractile response to potassium. O  lOnM PGE2; □  O.OlnM PGE2, both 
responses elicited from same vessels, the response in lOnM was elicited 
first, n=4. Responses in 15% oxygen and lpM  indomethacin. pEC5 0  
(-log1 0 M), mean (SEM), in lOnM 1.32 (0.01); in O.OlnM 1.62 (0.05). Mean 
change 0.31 (95% Cl 0.14 to 0.47), p=0.0099 Student's paired t test. The 
responses are expressed as a proportion of their own maximum. The 
response in lOnM PGE2  was 31% (95% Cl 12 to 50, p=0.014) reduced 
compared to the response in O.OlnM PGE2.
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Figure 6.5 Maximum relaxant responses (MRR) of vasodilators in 
lpM  indom ethacin, 10pM noradrenaline and 15% oxygen. MRR
expressed as % maximum relaxation. Mean (SEM): Aden = adenosine 
2.2% (1.2) n=16, ANP = atrial natriuretic peptide 0.0%, (0.0) n=4, Cica = 
cicaprost 89.0% (1.0) n=15, Crom = cromakalim 28.2% (2.4) n=16, Forsk = 
forskolin 98.8% (0.5) n=12, Nif = nifedipine 0.0% (0.0) n=4, PGE2 73.4% 
(5.0) n=15, SNP = sodium nitroprusside 2.9% (1.3) n=12. ANOVA of 
means: F ratio = 282.63, p<0.0001. Multiple comparisons: Forskolin vs 
cicaprost, borderline significant difference, but both significantly greater 
than all other agonists; PGE2 significantly greater than cromakalim, which 
was greater than remaining four agonists (see Appendix [Table A.5] for 
table of values of 95% Cl of pairwise differences).
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Figure 6 . 6  The effect of oxygen tension on the response to PGE2  in 
lpM  indomethacin and lOpM noradrenaline. #  2% oxygen; O  15% 
oxygen; n=7. MRR and pEC50s for above and for time controls, see Tables
6.1 and 6.2. Points are means, bars are SEM.
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Figure 6.7 The effect of oxygen tension on the response to cicaprost in 
lpM  indomethacin and lOpM noradrenaline. #  2% oxygen; O  15% 
oxygen; n=8 . MRR and pEC50s for above and for time controls see Tables
6.1 and 6.2. For comparison of extent of change induced by altering 
oxygen tension with extent of change in time controls, see Table 6.3. 
Points are means, bars are SEM.
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Figure 6 . 8  The effect of oxygen tension on the response to adenosine in 
lpM  indomethacin and 10|xM noradrenaline. #  2% oxygen; 0  15% 
oxygen; n=8 . MRR for above and for time controls see Tables 6.1 and 6.2. 
For comparison of extent of change induced by altering oxygen tension 
with extent of change in time controls, see Table 6.3. Points are means, bars 
are SEM.
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Figure 6.9 The effect of oxygen tension on the response to sodium 
nitroprusside (SNP) in l|iM indomethacin and 10|xM noradrenaline. #
2% oxygen; O  15% oxygen; n=8 . MRR for above and for time controls, 
see Tables 6.1 and 6.2. Points are means, bars are SEM.
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Figure 6.10 The effect of oxygen tension on the response to 
cromakalim in l|iM  indomethacin and lOjiM noradrenaline. #  2%
oxygen; O  15% oxygen; n=8 . MRR and pEC50s for above and for time 
controls see Tables 6.1 and 6.2. For comparison of extent of change 
induced by altering oxygen tension with extent of change in time controls, 
see Table 6.3. Points are means, bars are SEM.
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Figure 6.11 The effect of oxygen tension on the response to forskolin in 
lfxM indomethacin and 10pM noradrenaline. #  2% oxygen; O  15% 
oxygen; n=8 . MRR and pEC50s for above and for time controls, see Tables
6.1 and 6.2. Points are means, bars are SEM.
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Figure 6.12 O riginal tracing of CRRC to PGE 2  in 10pM 
noradrenaline, lfiM indomethacin and in A. 15% oxygen and B. 2% 
oxygen. Both responses to PGE2  in the presence of lpM  indomethacin 
and lOpM noradrenaline. A Bubbled with 15% oxygen giving oxygen 
tension of 105mmHg; B Bubbled with 2% oxygen giving oxygen tension 
of 23mmHg.
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Figure 6.13 The effect of oxygen tension on the response to PGE2  in 
10)xM noradrenaline in the absence of indomethacin. O  CRRC 1, 15% 
oxygen; #  CRRC 2, 2% oxygen; n  CRRC 3, 15% oxygen; Points are 
means, bars are SEM, n=7. Three consecutive responses to PGE2  in 
absence of cyclo-oxygenase inhibitor in 15% oxygen (CRRC 1 and 3) and 
2% oxygen (CRRC 2). Comparing the two responses in 15% oxygen, 
there was no significant difference in pEC5 0  (-log1 0 M): (mean [SEM] 8.49 
[0.11] vs 8.30 [0.16], p=0.24); or MRR (% maximum relaxation): (72.3% 
[5.8] vs 67.2% [8.4], p=0.26), all Student's paired t-test.
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Figure 6.14 The effect of oxygen tension on the response to PGE2  in 
lOpM noradrenaline and ljiM flubriprofen. O  CRRC 1,15% oxygen; #  
CRRC 2, 2% oxygen; □  CRRC 3,15% oxygen; Points are means, bars are 
SEM, n=4. Three consecutive responses to PGE2  in l|xM flubriprofen in 
15% oxygen (CRRC 1 and 3) and 2% oxygen (CRRC 2). Comparing the 
two responses in 15% oxygen, there was no significant change in pEC5 0  
(-log1 0 M): (mean [SEM]: 8.99 [0.09] vs 8 . 8 6  [0.16], p=0.23) or MRR (% 
maximum relaxation): (90.1% [1.7] vs 90.0% [1.5], p=0.13), all Student’s 
paired t-test.
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Figure 6.15 Effect of oxygen on the maximum relaxant response 
(MRR) to PGE2 in lpM  indomethacin, lpM  flubriprofen and absence 
of cyclo-oxygenase inhibitor (control). ANOVA of means: 15% oxygen, 
F ratio = 2.62, p=0.106; 2% oxygen, F ratio=12.95, p=0.001- multiple 
comparisons show no significant difference between MRR to PGE2 
comparing flubriprofen and indomethacin, but both significantly greater 
than control (see Appendix [Table A.7] for table of values of 95% Cl of 
pairwise differences).
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AGONIST 15% oxygen  
n= pEC5 0 PEC3 0 * MRR
2 % oxygen  
PEC5 0  pEC3 o* MRR
ADENOSINE 8 4.4 44.7***
(2.3) (5.4)
CICAPROST 8 6.74 6.95 87.4 7  7 4 *** 7  98*** 9 9  3***
(0.08) (0.08) (1.5) (0 .1 1 ) (0 .1 0 ) (0.3)
CROMAKALIM 8 6.62 _ 30.6 7.23** _ 72 4 ***
(0 .1 1 ) (2.9) (0.04) (2.9)
FORSKOLIN 8 6.46 6.64 98.9 7.06** 7.28** 99.8
(0.07) (0.08) (0 .8 ) (0.08) (0.07) (0 .2 )
p g e 2 7 8.89 9.06 80.4 9.41* 9.60* 98.5*
(0.14) (0.14) (5.1) (0.09) (0 .1 0 ) (0.7)
SNP 8 — _ 4.4 _ _ 25.7*
(1 .8 ) (6 .2 )
Table 6.1 Response to dilators in 15% and 2% oxygen (pEC50, 
pEC30*, and maximum relaxant response [MRR]). All values are mean 
(SEM). For definition of pEC5 0  and pEC30* (both -log1 0 M) see sections 
2.4 and 6.1.3, respectively; MRR expressed as % maximum relaxation. 
Statistical comparison between values in 15% oxygen and in 2% oxygen, 
Student’s paired t test, *p<0.01, **p<0.001, ***p<0.0001.
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AGONIST Time Control 1 
n= pEC5 0  pEC30* MRR
Time controls 2 
pEC5 0  pEC30* MRR
ADENOSINE 8 0 6 .1 *
(0 ) (1 .2 )
CICAPROST 7 6 .8 6 7.04 90.8 7.14* 7.33* 94.9*
(0.09) (0.08) (0 .8 ) (0.04) (0.03) (0.9)
CROMAKALIM 8 6.54 _ 25.8 6.79* _ 43.0***
(0.05) (3.5) (0.06) (4.6)
FORSKOLIN 4 6.34 6.52 98.7 6.47 6.69 99.2
(0.04) (0.06) (0.4) (0.13) ((0.13) (0.5)
PGE2 8 8.44 8.42 67.3 8.26 8.41 77.4
(0.19) (0.29) (8 .0 ) (0.07) (0 .1 0 ) (3.9)
SNP 4 _ _ 0 _ _ 6 . 6
(0 ) (3.0)
Table 6.2 Response to dilators in time control experiments with both 
responses in 15% oxygen (pEC50, pEC30*, and maximum relaxant 
response [MRR]). All values are mean (SEM). For definition of pEC5 0  and 
pEC30* (both -log1 0 M) see sections 2.4 and 6.1.3, respectively; MRR 
expressed as % maximum relaxation. Statistical comparison between 
values from two consecutive responses in 15% oxygen carried out under 
same time protocol as Table 6.1, Student's paired t test, *p<0.01,
***p<0 .0 0 0 1 .
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AGONIST 15% to 2% oxygen Time controls (15% oxygen)
CHANGE: CHANGE:
n= pEC5 0  pEC30* MRR n= pEC5 0  pEC30* MRR
ADENOSINE 8 -  -  40.3 ** 8 -  -  6.1
(5.2) (1.2)
CICAPROST 8 1.00*** 1.02 *** 11.9 ** 7 0.28 0.28 4.1
(0.09) (0.09) (1.3) (0.07) (0.06) (0.9)
CROMAKALIM 8 0.61 * -  41.8 *** 8 0.24 -  17.1
(0.11) (3.3) (0.06) (1.7)
Table 6.3. Comparison of changes in PEC5 0 , pEC30* and maximum 
relaxant response (MRR, %), oxygen tension vs time controls, for 
adenosine, cicaprost and cromakalim. Values are mean differences (SEM). For 
definition of pEC5 0  and pEC30* (both -log1 0 M) see sections 2.4 and 6.1.3, 
respectively; MRR expressed as % maximum relaxation. Statistical comparison: 
change induced by decreasing oxygen from 15% to 2% vs spontaneous change 
in time controls (two consecutive responses, same time protocol as oxygen 
experiments, but both responses in 15% oxygen): *p<0.05, **p<0.001, 
***p< 0  oooi, Student’s t-test.
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6.3 Discussion.
These data demonstrate that oxygen tension modulates the effect of PGE2  
on the response of the ductus arteriosus to noradrenaline (Figures 6.1 to 
6.3). The effect of PGE2  on both the MCR and the sensitivity of the vessel 
to noradrenaline was potentiated by fetal oxygen tension, but the 
potentiating effect of fetal oxygen tension was most pronounced on the 
MCR (Figure 6.1). However, it required both fetal oxygen tension and 
physiologically elevated PGE2  to cause this profound inhibition: oxygen 
had no effect on the MCR to noradrenaline in 0.01 nM PGE2  but massively 
inhibited the response of MCR to noradrenaline in InM PGE2  (Figures 6.1 
to 6.3). These data point to an interesting synergy between these two 
fundamental control systems of the ductus in regulating its response to 
noradrenaline. It can readily be envisaged that following birth with the 
elimination of circulating PGE2  (Clyman et al, 1980c) and the rise in 
arterial oxygen tension (Heymann and Rudolph, 1975), that the response 
of the ductus to both local and circulating catecholamines is uncovered. 
The interaction between these factors points to the complexity of the 
control systems which regulate ductal patency at birth.
Interestingly, the effect of PGE2  on the response of the ductus to 
noradrenaline is not specific: PGE2  also inhibits the vessel’s response to 
potassium-induced contraction (Figure 6.4). The effect of PGE2  on 
potassium implies that PGE2  acts at some fundamental cellular level, i.e. it 
excludes a specific effect on the noradrenaline receptor-effector system 
(i.e. receptor, G protein, second messengers). This implication has been 
supported by the observation that PGE2  inhibits the sensitivity of the 
contractile proteins to [Ca2+]i, [Crichton et al ,1994]). This effect is 
probably mediated by stimulation of adenylate cyclase, as PGE2  only has 
an effect in the presence of the phosphodiesterase inhibitor, IB MX, and 
forskolin also inhibits the sensitivity of the contractile proteins of the 
ductus to [Ca2+]i (Crichton CA, Smith GCS, Smith GL, paper in
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preparation).
The interaction between PGE2, oxygen and noradrenaline could also be 
demonstrated by pre-contracting the ductus with 10|xM noradrenaline and 
obtaining CRRC to PGE2  in low and high oxygen tension (Figures 6 . 6  
and 6.12). I then sought to determine whether this inhibitory effect of 
neonatal oxygen tension on the response of the ductus to PGE2  was 
specific to this agonist or whether it was a general property of 
vasodilators. As Figures 6.7 to 6.11 illustrate, oxygen tension modulates 
the sensitivity of the ductus to a range of dilators with different 
mechanisms of action, including a prostanoid other than PGE2  (cicaprost, a 
stable PGI2  mimetic [Stiirzebecher et al, 1986]); by activating adenylate 
cyclase directly (forskolin [Seamon and Daly, 1981]); by stimulating 
guanylate cyclase (SNP [Walsh and Mentzer, 1987]); by hyperpolarising 
the membrane through activation of ATP-sensitive potassium channels 
(cromakalim [Bray et al, 1991]); and, by adenosine, which can cause 
vasodilation in different vessels by different mechanisms (Merkel et al, 
1992 [its mechanism in the ductus has not been elucidated]).
These data contradict the hypothesis that this effect of oxygen is specific 
to PGE2  and suggest that the effect(s) of oxygen also lie at a fundamental 
cellular event modulating smooth muscle contractility. The model for the 
oxygen-induced contraction proposed by Nakanishi et al (1993)- see 
section 1 .2 .1 - namely that oxygen contracts the ductus by depolarising the 
membrane through the closure of ATP-sensitive potassium channels would 
predict that cromakalim would not be affected by changes in oxygen 
tension. As discussed in section 1.2.1, there is evidence that oxygen also 
contracts the ductus by a mechanism independent of changes in the 
membrane potential. The effect of oxygen on the response of the ductus to 
cromakalim (Figure 6.10) is another piece of evidence for a membrane- 
independent effect of oxygen. Interestingly, our work on the 
permeabilised ductus indicates that at ambient oxygen (i.e. physiologically
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elevated), the intrinsic sensitivity of the contractile proteins of the ductus 
to [Ca2+]j is higher than the aorta and pulmonary artery, the vessels it 
connects and, indeed, any other smooth muscle preparation studied 
(Crichton et al, 1994). We did not have the equipment to study the 
sensitivity of the permeabilised ductus to [Ca2+]i in fetal oxygen tension 
but it would clearly be of interest to elucidate the effect of oxygen on this 
variable. It may be at this level that oxygen exerts its membrane- 
independent effect.
These data indicate that in infants with cyanotic congenital heart defects 
which are ductus dependent, PGEj has the potential to be self-limiting: its 
therapeutic effect (increasing arterial oxygen tension) will decease the 
sensitivity of the ductus to its effect. The data in Figures 6.7 to 6.11 
indicate that this will be a problem with any vasodilator used in this clinical 
setting.
The ability of adenylate cyclase activation by forskolin to reverse 
completely the combined contractile effects of indomethacin, elevated 
oxygen and 10p,M noradrenaline (Figure 6.11) suggests a major role for 
this enzyme in the regulation of ductal tone. The maximal effect of 
forskolin was significantly greater than PGE2, which is also believed to 
dilate the ductus through adenylate cyclase (Walsh and Mentzer, 1987; 
Crichton et al, 1994). The implication of this is that there is adenylate 
cyclase in ductal smooth muscle which is not coupled to the PGE2  
receptor/effector mechanism.
The effects of PGI2  on other blood vessels are coupled to adenylate 
cyclase (Dembinska-Kiec et al, 1979; Miller et al, 1979). Cicaprost, a 
stable, selective PGI2  mimetic (Stiirzebecher et al, 1986), caused a greater 
maximal relaxation than PGE2  (Figure 6.1). If, as is likely, the ductal 
receptor for PGI2  is also coupled to adenylate cyclase, this implies that 
there is actually more of the enzyme coupled to the receptor for PGI2  than 
PGE2, although, clearly, other explanations exist. Despite the fact that PGI2
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is the main prostanoid formed by the ductus, PGE2  has always been seen 
as the more important prostaglandin in the regulation of ductal tone as, in 
the lamb, it is over 1 0 0 0  times more potent than PGI2  (see section 1.2.3 for 
discussion and references). Converting the data in Figure 2 to molar 
concentrations, PGE2  was about 70 times more potent than cicaprost. 
Taken in combination with its greater MRR than PGE2  these data imply a 
physiological role for PGI2  in the regulation of the rabbit ductus. It remains 
to be seen why studies on the lamb using PGI2  yielded such different 
results. It may represent a species difference, it may reflect a difference 
between the synthetic analogue (cicaprost) and the natural agonist (PGI2), 
or it may reflect the nature of the pre-contraction. Given the potential for 
use of PGI2  in ductus-dependent circulation, the physiological role of PGI2  
in the regulation of the ductus needs to be clarified.
The contractile response of the vessel to indomethacin declined from 
CRRC 1 to CRRC 2 (time controls). This was in spite of the fact that the 
total amount of active tone (i.e. with lOpM noradrenaline as well) actually 
increased over the same period. This decline in response to indomethacin 
may be related to the increased response to some, but not all of the dilator 
agonists with time. It remains to be seen which cellular events are involved 
in mediating these effects.
Compared with the ability of forskolin to cause complete relaxation in 15% 
oxygen, 10|xM noradrenaline and lpM indomethacin, SNP induced only a 
3% relaxation (Figure 6.1). This suggests that the main second messenger 
in the control of the ductus arteriosus is adenylate cyclase rather than 
guanylate cyclase. Indeed, in the lamb ductus, SNP stimulates both 
adenylate and guanylate cyclase (Walsh and Mentzer, 1987), and the small 
effect of SNP may be due to an action on adenylate cyclase. Whatever the 
case, the small effect of the nitric oxide donor, SNP, suggests that while 
endogenous nitric oxide may have a role in dilating the ductus (see section
1.2.4), its role may be a relatively minor one.
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The minor effect of adenosine and SNP on the ductus in 15% oxygen 
differs from previous studies. It has been suggested that adenosine has a 
physiological role in maintaining ductal patency in utero: micromolar 
concentrations reverse oxygen-induced contraction of the vessel and its 
circulating concentrations correlate with oxygen tension (inversely) and 
ductal blood flow (directly) during ventilation of the fetal lungs with 
oxygen (Mentzer et al, 1985). Similarly, some nitrovasodilators have been 
demonstrated as having greater efficacy than PGEj in reversing the 
oxygen-induced contraction of the isolated lamb ductus (Walsh and 
Mentzer, 1987). These data for both agonists seem to be at odds with my 
results. This may reflect a species difference or the use of noradrenaline to 
pre-contract the vessel in the present study. Perhaps the most likely 
explanation, however, is that neither of the other studies used 
indomethacin. I have found that the ductus is more sensitive to 
vasodilators other than PGE2  in the absence of indomethacin (see Chapter
5). This is almost certainly due to synergy between endogenous PGE2  and 
the exogenous dilator.
In the absence of cyclo-oxygenase inhibition, elevated oxygen still 
decreased the pEC5 0  and MRR of the ductus to PGE2  (Figure 6.13). The 
extent of the effect of oxygen on the pEC5 0  to PGE2  was unaffected by 
cyclo-oxygenase inhibition. This indicates that the effect of oxygen on the 
pEC 5 0  of the ductus to PGE2  is not mediated by a cyclo-oxygenase 
product. However, cyclo-oxygenase inhibition did alter the maximum 
response to PGE2: the MRR to PGE2  was increased in the presence of 
both indomethacin and flubriprofen in 2% but not 15% oxygen, compared 
with control (Figure 6.15).
As discussed at length in Chapter 5, when comparing the response of 
tissues to exogenous prostaglandins in the presence and absence of cyclo- 
oxygenase inhibitors, there can be an apparent decrease in sensitivity to 
prostaglandins in the absence of a cyclo-oxygenase inhibitor as the effects
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of exogenous prostaglandins are being super-imposed on the effects of 
endogenous prostaglandins. It could be argued that the decrease in MRR 
to PGE2  in 2 % oxygen in the absence of indomethacin or flubriprofen is 
such a case. However, in the presence of indomethacin or flubriprofen, 
exogenous PGE2  caused complete relaxation in 2% oxygen. In the 
absence of these drugs it did not. This phenomenon is a change in an 
absolute response, not a shift in sensitivity and cannot, therefore, be 
explained in the above terms. These data suggest that an endogenous 
prostanoid prevents complete relaxation of the vessel to PGE2, but that its 
effect is only seen in fetal oxygen tension. Several models of the 
interaction between the cyclo-oxygenase product and oxygen fit these 
data: ( 1 ) its rate of synthesis may vary inversely with oxygen tension; (2 ) 
its receptor/effector mechanism may be modulated by oxygen tension; or, 
(3) its effect may be masked by elevated oxygen tension e.g. if the cyclo- 
oxygenase product and raised oxygen tension both decreased the 
response to PGE2  by the same mechanism.
By inhibiting the response to PGE2, this cyclo-oxygenase product will 
make the ductus contract. These data are, to my knowledge, the first 
evidence for a constrictor prostanoid released by the ductus. The data 
suggest that when indomethacin is administered in patent ductus 
arteriosus, while it will cause contraction by removing the dilator effects of 
PGE2  and PGI2, it will also have a dilator effect itself by removing this 
endogenous constrictor prostanoid. If this prostanoid has an important 
physiological role in neonatal closure of the vessel, it may eVen explain the 
tendency of the vessel to re-open after initial closure by indomethacin in 
PDA (Gersony, 1986). Further experimental work is required to identify 
this prostanoid and to clarify its physiological role in regulating patency of 
the ductus arteriosus.
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Chapter 7. Contractile effects of prostanoids on the ductus 
arteriosus.
In the preceding chapter, evidence was presented that cyclo-oxygenase 
inhibition potentiated the dilator effect of PGE2 , implying the presence of a 
endogenous contractile prostanoid. For this to be the case, there must be 
one or more types of prostanoid receptor in the ductus coupled to 
contractile pathways. There have, however, been very few studies of 
contractile effects of prostaglandins on the ductus. It has been 
demonstrated that PGF2ot contracts the ductus (Starling and Eliott, 1974). 
However, that finding has been largely discounted due to the fact that 
these authors studied the effect of a single, very high concentration of 
PGF2 a (about 7p,M). Another study failed to demonstrate any contractile 
effect of native TxA2  (Coceani et al, 1978a). This study was flawed by 
the fact that the system used for generating TxA2  also generated PGE2 , 
picomolar concentrations of which inhibit the response of the ductus to 
constrictors (see Chapter 5).
The existence of contractile receptors on the ductus arteriosus would be 
expected from the general properties of other tissues also under the control 
of prostaglandins, such as other vascular smooth muscle, myometrium and 
platelets. In these systems, the inhibitory effects of prostanoids are all 
opposed by stimulatory effects, for instance myometrium has contractile 
EPj, EP3, FP and TP receptors and relaxant EP2, IP and DP receptors 
(Senior et al, 1991 and 1992); platelets have pro-aggregatory EP3  and TP 
receptors and anti-aggregatory DP and IP receptors (Whittle et al, 1983; 
Armstrong et al, 1985 and 1989; Matthews and Jones 1993). The current 
view of prostaglandin pharmacology in the ductus arteriosus is that it is a 
relatively unique tissue in having purely inhibitory prostaglandin effects 
(Clyman, 1987; Coceani and Olley, 1988). However, as stated above, the 
data which havefailed to demonstrate contractile effects aresparse, out of
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date and methodologically flawed.
The prostanoid receptors mediating contraction of smooth muscle are 
almost exclusively EPj, EP3 , TP and FP (Coleman et al, 1990). A range of 
selective agonists and some receptor antagonists are available with activity 
at these receptors. There has been no study, to my knowledge, of the 
effects of synthetic contractile prostanoids on the ductus arteriosus of any 
species. I sought to characterise the effect on the fetal rabbit ductus 
arteriosus of synthetic and native prostanoids with activity at the 
prostanoid receptors which mediate contraction in other smooth muscle 
preparations. The effects on the ductus arteriosus of sulprostone and 
GR63799X, (potent, selective agonists of the EP! and EP3  receptors 
[Bunce et al, 1990; Coleman et al, 1990]) and U46619 (a potent agonist 
of the TP receptor [Coleman et al, 1990]) were studied. The highly 
selective FP receptor agonist, fluprostenol (Coleman et al, 1990), is no 
longer commercially available and the potency of the native FP receptor 
agonist, PGF2ot, had to be compared with the other agonists to make 
inferences regarding the presence of an FP receptor on the ductus.
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7.1 Methods.
The baths were bubbled with a gas mixture of 15% 0 2, 5% C 02, and 80% 
N2, which resulted in a P 0 2  of 100-1 lOmmHg. When mounted, the vessels 
were stretched to 0.6g.tension and this was re-set 60 minutes later. The 
PSS was changed at 30 and 60 minutes following mounting and the 
vessels were allowed to incubate for 90 minutes prior to addition of 
indomethacin. All responses, contractile and relaxant, were obtained in the 
presence of lpM  indomethacin (added at least 30 minutes before eliciting 
all responses) which contracts the ductus (see section 1.2.3). The PSS was 
changed at least 3 times after a given response was completed.
7.1.1 Concentration contraction response curves.
Following the indomethacin contraction, the vessel was relaxed with either 
300nM forskolin or lOnM PGE2. When the fall in tension had equilibrated, 
a standard contraction to lOpM noradrenaline was obtained. The PSS was 
changed 3 times and indomethacin added. After at least 30 minutes, the 
vessel was relaxed by the same method, and a cumulative concentration 
contraction response curve (CCRC) obtained to the given prostanoid. 
When the effect of an antagonist was studied, a second CCRC was 
obtained in the presence of the antagonist and the change in sensitivity 
compared to the same number of concurrent time controls in the presence 
of the antagonist's vehicle.
7.1.2 Concentration relaxation response curves.
Essentially, the methods were the same as outlined in section 4.1. 
Following the indomethacin contraction, the vessel was further contracted 
by addition of 2M KC1 to a bath K+ concentration of 25mM. The 
combination of 25mM K+ and lpM indomethacin caused a sustained, 
stable elevation of tone which was always obtained within 1 0  minutes of 
adding the KC1. After 10 minutes, a cumulative concentration relaxation 
response curve (CRRC) was obtained. The first CRRC was a control
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response to PGE2. At least 55 minutes was allowed between consecutive 
CRRC. The second CRRC was obtained 10 minutes after addition of a 
given prostanoid (itself added 10 minutes after the KC1). The change in 
response parameters to PGE2  was compared with the initial control 
response. The extent of change between the two CRRC was compared 
with the extent of change in the response parameters of concurrent time 
controls in the presence of the appropriate vehicle.
7.1.3 Quantification of responses.
The magnitude of the contractile response of prostanoids was expressed as 
a proportion of the maximum response to noradrenaline (10|iM) of the 
same vessel in the same conditions (i.e. 300nM forskolin or lOnM PGE2). 
The magnitude of the relaxation induced by PGE2  in the presence of a 
contractile prostanoid and the magnitude of the relaxation induced by 
PGE2  in the second time control were expressed as a proportion of an 
initial control response (Coleman, 1987) The sensitivity of the vessel to 
both contractile and relaxant responses was expressed as the EC5 0  or the 
pEC50, see section 2.4 for definition.
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7.2 Results.
In 300nM forskolin, both the potent TP receptor agonist, U46619, and the 
potent EP1 /EP3  agonist, sulprostone, caused concentration dependent 
contractions of the ductus in the nanomolar range (Figure 7.1). The 
agonists were of very similar potency but the maximum response to 
U46619 was greater than sulprostone. Figure 7.2 illustrates a typical 
response to U46619. The TP receptor antagonist, EP 092 (Armstrong et 
al, 1985) caused a parallel rightward shift of the U46619 CCRC (Figure 
7.3). In 300nM forskolin, PGF2a had no effect at concentrations of 1- 
lOnM but caused relaxation at higher concentrations. GR63799X caused 
variable contractions at 3-10nM but caused marked relaxation at 30nM. In 
the presence of lOnM PGE2, U46619, sulprostone and GR63799X caused 
similar concentration-dependent contractions of the ductus arteriosus 
whereas PGF2a had no effect (up to 30pM, Figure 7.4).
There was no significant difference in the response to 10|iM noradrenaline 
in 300nM forskolin (mean 11.8mN [1.1] n=12) and that in lOnM PGE2  
(mean [response prior to U46619, sulprostone and GR63799X only] = 
13.4mN [0.5], n=21; p=0.0852). Expressed as a percentage of the response 
of the same vessel to 10pM noradrenaline under the given conditions, the 
maximum responses to U46619 and sulprostone in 300nM forskolin (data- 
see above) were significantly greater than in lOnM PGE2  (U46619: 29.9% 
[7.4], n=9, p<0.0001; Sulprostone 17.8% [2.1], n=6 , p=0.0142).
Compared with concurrent time and vehicle control responses to PGE2, 
there was no significant change in the sensitivity of the ductus to PGE2  in 
the presence of lOnM U46619 or lOnM PGF2ot (Figure 7.5). There was, 
however, a significant decrease in the pEC5 0  to PGE2  in lOnM sulprostone 
and 3|iM sulprostone (Figure 7.5). Calculated from the estimate of the 
difference from time controls, lOnM sulprostone increased the EC5 0  to 
PGE2  by 119% and 3pM sulprostone increased it by 157%.
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Figure 7.1 Contractile effect of U46619 and sulprostone in 300nM 
forskolin. U46619 (O  n=8 ) and sulprostone (□  n=4), in the presence of 
lpM  indomethacin and 300nM forskolin. Contraction at each 
concentration is expressed as a proportion of the same vessel’s response to 
lOpM noradrenaline in lpM indomethacin and 300nM forskolin. U46619: 
pEC5 0  (-log1 0  M) = 7.47 (SEM 0.13), n=8 , EC5 0  = 33nM; Sulprostone: 
pEC5 0  = 7.37 (SEM 0.20), n=4, EC5 0  = 42nM. There was no statistically 
significant difference in the pEC50s (p=0.6711). The maximum response to 
U46619 was 92.8% (SEM 5.8) that of 10|xM noradrenaline, sulprostone 
was 49.1% (SEM 7.4) that of 10pM noradrenaline, which was significantly 
less than U46619 (p=0.0085). All comparisons, Mann-Whitney U test. 
Points are means, vertical bars are SEM.
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Figure 7.2 Original tracing of response of ductus arteriosus to U46619 
(l-1000nM). Preceding control contraction to 10|xM noradrenaline (NA), 
both responses in the presence of lpM  indomethacin and 300nM 
forskolin.
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Figure 7.3 Effect of EP 092 on response to U46619 in 300nM forskolin.
Response of the ductus arteriosus to U46619 in the presence of lpM 
indomethacin and 300nM forskolin, in the presence ( • )  and absence (O) 
of lpM  EP 092, both n=4. Contraction of a given vessel is expressed as a 
% of its own maximum. Points are means, vertical bars are SEM. Compared 
with the initial control response, the mean change in pEC5 0  [-log1 0  M] in 
lpM  EP 092 was -0.48 (0.20), n=4 vs time control 0.03 (0.05), n=4; 
p=0.0304, Mann-Whitney U test.
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Figure 7.4 Contractile response to U46619, sulprostone, GR63799X 
and PGF2a in lOnM PGE2. U46619 (O n=9), sulprostone ( •  n=6 ), 
GR63799X (□  n=6 ) and PGF2a (■ n=6 ) in the presence of l|xM 
indomethacin and lOnM PGE2. Contraction at each concentration is 
expressed as a proportion of the same vessel's response to lOjiM 
noradrenaline in the presence of lpM  indomethacin and lOnM PGE2. 
Points are means, vertical bars are SEM. Looking at the response at each 
concentration by ANOVA, there were no significant differences in the 
response to U46619 and sulprostone, and sulprostone and GR63799X at 
any concentrations. The responses to U46619 and GR63799X were similar 
but the response to GR63799X was significantly less than the response to 
U46619 at lOOnM and 300nM (see Appendix [Tables A . 8  and A.9 
respectively] for table of values of 95% Cl of pairwise differences).
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Figure 7.5 Effect of contractile prostanoids on the sensitivity of the 
ductus arteriosus to PGE2. Data are the mean change in pEC50 to PGE2 
between an initial control response and a subsequent test response, 
comparing test responses in the presence of a contractile prostanoid with 
time controls in the presence of the appropriate vehicle. The mean (SEM) 
change in pECS0 ('l°gio M) in lOnM U46619 was 0.06 (0.07) n=7 vs time 
control 0.11 (0.07), n=8; p=0.7273; in lOnM PGF2a was 0.07 (0.07), n=7 
vs time control 0.15 (0.06), n=8; p=0.4863; in lOnM sulprostone was -0.17 
(0.03), n=4 vs time control 0.18 (0.07), n=4; p=0.0304, point estimate of 
difference=0.34 (95% Cl 0.12-0.58); in 3pM sulprostone was -0.41 (0.07), 
n=12 vs time control 0.03 (0.05), n=7; p=0.0015, point estimate of 
difference = 0.42 (95% Cl 0.23-0.66). All comparisons Mann-Whitney U 
test.
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7.3 Discussion.
The preceding chapter presented data which suggested contractile effects 
of prostanoids in the ductus. This hypothesis predicts that the ductus 
would have prostanoid receptors coupled to contractile pathways. The 
data presented in this chapter strongly support this hypothesis.
This study provides strong evidence that the fetal rabbit ductus arteriosus 
has thromboxane receptors (TP receptors): namely, the ductus contracts to 
nanomolar concentrations of the stable thromboxane mimetic, U46619 
(Figures 7.1 to 7.4), none of a range of synthetic prostanoids with activity 
at other contractile prostanoid receptors were more potent than U46619 
(Figure 7.4) and the selective TP receptor antagonist, EP 092 (Armstrong 
et al, 1985), caused a rightward shift in the concentration response curve 
to U46619 (Figure 7.3). Furthermore, the potency of EP 092 on the ductus 
was consistent with its potency on the TP receptor of the adult rabbit aorta 
(Armstrong etal, 1985).
Only one other study has, to my knowledge, looked for thromboxane 
effects on the ductus arteriosus, where native TxA2  was prepared through 
incubation of cyclic endoperoxides (PGG2  and PGH2) with microsomal 
fractions of human platelets or guinea pig lungs. This mixture did not 
contract the lamb ductus arteriosus (Coceani et al, 1978a) The 
discrepancy between that work and the current study may be due to one 
or more of the following: species difference, failure of the bio-generation 
system to produce sustained, high concentrations of TxA2  or, perhaps most 
likely, due to generation of PGE2  by the reaction mixture. Whether the last 
of these is the explanation depends on the relative potency of PGE2  in 
relaxing the vessel and TxA2  in contracting it plus the relative proportions 
of TxA2  and PGE2  produced by the reaction mixture in the lamb study. I 
have found that picomolar concentrations of PGE2  inhibit the response of 
the ductus to vasoconstrictors (see Chapter 5) whereas in the present
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study I have described an EC5 0  for U46619 of 33nM. There is clearly 
potential, therefore, for relatively small concentrations of contaminant 
PGE2  to mask the effect of TxA2. Quantifying the response of the lamb 
ductus to U46619 would resolve this question.
The present study also provides strong evidence for the existence of a 
contractile EP receptor on the ductus arteriosus, as the vessel contracted to 
nanomolar concentrations of sulprostone (Figure 7.1), which is a potent 
agonist of contractile EP receptors (see below) in many tissues (Coleman 
et al, 1990) and is ineffective at the dilator EP receptor on the ductus (see 
Chapter 4). It is possible that this effect of sulprostone was due to agonism 
of non-EP contractile prostanoid receptors, namely TP or FP receptors. This 
is highly unlikely, however, as sulprostone was equipotent with U46619 
and more potent than PGF2ot. In other smooth muscle preparations, 
sulprostone is almost 200-fold less potent than PGF2a at FP receptors and 
500-fold less potent than U46619 at TP receptors (Coleman et al, 1988). 
Furthermore, lOnM sulprostone decreased the sensitivity of the ductus to 
the dilator effect of PGE2, whereas U46619 and PGF2a did not (Figure 
7.5). Even if the TP receptor of the ductus were unique in that sulprostone 
and U46619 were equipotent agonists, it would not explain why lOnM 
sulprostone had this effect whereas lOnM U46619 did not.
The advantage of looking at contractile effects of prostanoids in lOnM 
PGE2  was that this eliminated the effect of agonism of the dilator EP 
receptor of the ductus by prostanoids. For instance GR63799X is a potent 
agonist of contractile EP receptors in a number of tissues (Bunce et al,
1990), but it is also a partial agonist of the ductal EP receptor about 700 
times less potent than PGE2  itself (see Chapter 4). This means that the 
effect of 1|liM GR63799X on the EP4  receptor would be equivalent to 
about 1.5nM PGE2. In the presence of lOnM PGE2, therefore, even very 
high concentrations of GR63799X cause only very small additional 
relaxation and a more reliable CCRC is obtained. In lOnM PGE2,
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GR63799X elicited contraction of the ductus with a similar potency to 
sulprostone and only slightly less potent than U46619 (Figure 7.4), which 
supports my conclusion that the ductus has a contractile receptor for 
PGE2. In other smooth muscle preparations, GR63799X is more than 200- 
fold less potent than PGF2 a at FP receptors and about 50-fold less potent 
than U46619 at TP receptors (Bunce et al, 1990).
Contractile effects of PGE2  are mediated through the EPj and EP3  
receptors (Coleman et al, 1990). Sulprostone and GR63799X are both 
more potent than PGE2  at the EP3  receptor and roughly equipotent with 
PGE2  at the E?i receptor (Bunce et al, 1990; Coleman et al, 1990). The 
data presented above, therefore, do not resolve whether the contractile EP 
receptor on the ductus is EPj or EP3. I constructed experiments to 
elucidate the effect of the selective EPi receptor antagonist, AH6809 
(Coleman et al, 1990), on the sensitivity of the ductus to sulprostone and 
GR63799X. However, I found that AH6809 caused direct relaxation of 
the vessel even in the absence of PGE2  (data not shown) which would 
interfere with analysis of any effect due to receptor blockade. A similar 
finding has been observed in other tissues and may be due to an action of 
AH6809 on phosphodiesterase (Coleman, 1987).
The EP3  receptor induces contraction by decreasing intracellular 
concentrations of cAMP (Coleman et al, 1990). As discussed in Chapters 
1 and 6 , PGE2  dilates the ductus by increasing cAMP. Stimulation of the 
EPj and TP receptors induce contraction independently of effects on 
cAMP (Coleman et al, 1994b). The fact that sulprostone decreased the 
sensitivity of the ductus to PGE2, whereas U46619 did not, suggests that 
sulprostone has a specific inhibitory effect on cAMP and, therefore, that its 
effect on the ductus is likely to be on an EP3  receptor. This needs to be 
confirmed by other techniques.
Recent studies have been described studying EP receptors at the 
molecular level (Namba et al, 1993; Sugimoto et al, 1993). The EP
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receptor subtypes present in the ductus could be described definitively by 
analysis of mRNA sequences in ductal smooth muscle, either by Northern 
blot or in situ hybridization. The physiological balance between 
contractile and dilator EP effects in the ductus could be better clarified 
with more potent, selective agonists and antagonists, which are not yet 
available.
No data were found to support the existence of an FP receptor on the 
ductus.
Applying these data to the physiological control of the ductus, it would be 
anticipated that the dilator EP receptor is active in fetal and early neonatal 
life and that closure of the vessel would be associated in a shift in the 
relative activation of the contractile EP receptor over the dilator EP 
receptor in the face of a given concentration of PGE2. It would also be 
expected that the ductus would develop contractile EP and TP receptors 
with advancing gestational age.
Increasing arterial oxygen tension is a feature of the neonatal circulation 
and oxygen causes direct contraction of the ductus (see section 1.2.1). In 
view of this, it is paradoxical that increasing oxygen tension increases the 
release of PGE2  by the isolated ductus arteriosus (Coceani et al, 1986) 
given that it is a potent dilator of the vessel (see section 1.2.3). These data 
make sense of this fact, particularly as increasing oxygen decreases the 
sensitivity of the ductus to the dilator effect of PGE2  (see Chapter 6 ). It 
may be that oxygen is one factor which regulates the balance of 
contractile and relaxant EP effects on the ductus.
It might be argued that the presence of TP receptors on the ductus is of no 
physiological significance, as the ductus does not synthesise TxA2  (Pace- 
Asciak and Rangaraj, 1977). However, the vessel may be exposed to TxA2  
as it closes when blood clots in the lumen as TxA2  is released following
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platelet aggregation. Alternatively, the TP receptor is also stimulated by the 
cyclic endoperoxides, PGG2  and PGH2  (Coleman et al, 1990), and 8 -epi- 
PGF2a (Baneijee et al, 1992). As oxygen stimulates the synthesis of all 
prostaglandins by the ductus (Coceani et al, 1986) it may be that the TP 
receptor is involved in ductal closure by mediating contractile effects of 
PGG2  and PGH2 , although this would be distinct from the direct contractile 
effect of oxygen which is not blocked by cyclo-oxygenase inhibitors 
(Smith and McGrath, 1988). Alternatively, increasing oxygen can stimulate 
the release of 8 -epi-PGF2a (Morrow et al, 1990), a potent TP receptor 
agonist (Banerjee et al, 1992), the synthesis of which is cyclo-oxygenase 
independent (Morrow et al, 1990). Finally, TP receptors can be stimulated 
by 15-hydroperoxy metabolites of arachidonic acid (Van Diest et al,
1991). There is no study to my knowledge which has examined whether 
the oxygen-induced contraction of the ductus is altered by TP receptor 
blockade.
These data also have relevance to the therapeutic use of indomethacin to 
close the ductus in premature infants where the vessel fails to close 
spontaneously (see Gersony, 1986, for review). Indomethacin contracts the 
ductus because the net effect of all prostaglandins synthesised by the 
ductus is dilator. However, since the ductus has contractile prostanoid 
receptors, part of the contractile effect of indomethacin (mediated by 
eliminating dilator effects of PGE2  and PGI2 ) may be offset by eliminating 
contractile effects of PGE2  and TP receptor stimulation. Given that the 
dilator effect of PGI2  appears to be somewhat dependent on the presence 
of PGE2  (see Chapter 5) it may be that a selective EP4  receptor antagonist 
(see Chapter 4) would be a more effective constrictor of the ductus than 
indomethacin.
Considering the use of intravenous PGEj or PGE2  to dilate the ductus in a 
range of congenital heart defects (Gersony, 1986) the current data suggest 
that the dilator effect of EP4  stimulation may be offset somewhat by
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activation of the contractile EP receptor. Indeed, the present data may 
explain the failure of this therapy in some infants. A selective EP4  agonist 
would be expected to be a more effective dilator of the ductus than PGEj 
or PGE2 , as well as having fewer adverse effects (see Chapter 4).
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Chapter 8. General discussion.
The specific aims outlined in section 1.6 have been largely achieved, and 
are discussed in detail in each of the chapter discussions. Furthermore, the 
general aims, of improving the understanding of the control of ductal 
closure in the neonate and identifying promising new avenues for the 
development of better drugs in the therapeutic control of the ductus, have 
also been achieved. In this chapter, I will try briefly to bring together some 
of the main findings of individual chapters into more general control 
models of ductal closure and clinical hypothesis for drug development.
8.1 A model for ductal closure in the neonate.
A major finding of this work was that PGE2  and oxygen tension interact in 
the regulation of ductal smooth muscle tone (Chapter 6 ). As discussed in 
Chapter 1, the main factors identified which stimulate contraction of the 
ductus after birth are decreasing circulating concentrations of PGE2  and 
increasing arterial oxygen tension and, as discussed in Chapter 6 , these 
factors act synergistically to promote contraction of the ductus. The 
factors which initiate the elimination of circulating PGE2  and the rise in 
oxygen tension at birth are ventilation of the lungs, the reversal of hypoxic 
pulmonary vasoconstriction and the development of normal pulmonary 
function. As discussed in Chapter 1, the patent ductus in the transitional 
circulation of the neonate improves pulmonary blood flow and increases 
arterial oxygen tension. A feedback loop is proposed between the patency 
of the ductus, its effects on lung function, and the effect of lung function 
on circulating PGE2  and oxygen tension. This control loop and the wider 
relationship between lung function and ductal closure are presented in a 
model, Figure 8.1.
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Figure 8.1 A model for the control of the ductus arteriosus in the 
transitional circulation. Arrows indicate a stimulatory effect unless there 
is a minus sign next to the point, in which case the effect is inhibitory.
154
8.2 The effects of oxygen on the ductus arteriosus.
As discussed above, the effect of oxygen is central to the closure of the 
ductus in the neonate. Understanding of the effects of oxygen had been 
incomplete. It was clear that the rise in oxygen that occurred at birth 
stimulated direct contraction of the vessel. However, it had been 
demonstrated that increasing oxygen tension also stimulated the release of 
PGE2  (Clyman et al, 1980a; Coceani et al, 1986). No explanation had 
ever been proposed why the factor which is central to stimulating the 
vessel to contract (oxygen) stimulates the release of the agent which is 
central to making the vessel relax (PGE2). Furthermore, following birth 
there is a massive decrease in the circulating concentrations of PGE2  
(Clyman et al, 1980c) but an apparent stimulation of its local release.
My work advances a series of explanations for this apparent anomaly. 
Firstly, the ductus has a TP receptor (see Chapter 7) which can be 
stimulated by PGH2  (Coleman et al, 1990a). PGE2  is formed by 
degradation of PGH2  in the ductus (see Chapter 1) and it follows, therefore, 
that if PGE2  is increased, PGH2  must also be increased. Any inhibitory 
effect of the PGE2  formed may, therefore, be offset by the contractile effect 
of increased PGH2. Secondly, the increase in formation of PGH2  is at least 
in part secondary to decreased PGI2  (see Needleman et al, 1981). The role 
of PGI2  has been discounted hitherto (Clyman, 1987; Coceani and Olley, 
1988). My work indicates that a decrease in the release of PGI2  will 
stimulate contraction as PGI2  almost certainly has a physiological dilator 
effect (see below). Thirdly, as oxygen tension rises, the sensitivity of the 
ductus to the dilator effect of PGE2  is inhibited (see Chapter 6 ). The net 
inhibitory effect of PGE2  may actually be reduced in raised oxygen 
tension, despite increased local concentrations. Finally, the PGE2  released 
will also stimulate the contractile EP receptor (see Chapter 7). It would be 
anticipated that responses mediated by this receptor will be increased 
following birth or in raised oxygen tension.
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A model for the effect of oxygen to promote contraction of the ductus is 
outlined in Figure 8.2. This model incorporates both the direct contractile 
effect of oxygen by depolarising the vessel, the membrane-independent 
effect and its effects on prostaglandin function.
One of the areas of study of the ductus which warrants further 
investigation is the mechanism of the membrane-independent effect of 
oxygen on the ductus. A particularly promising line of investigation would 
follow up the work on the factors controlling the sensitivity of the 
contractile proteins of the ductus to calcium. In elevated oxygen tension, 
the selectively permeabilised ductus is more sensitive to calcium than any 
other smooth muscle studied (Crichton et al, 1994). It would be 
interesting to establish whether the membrane-independent effect of 
oxygen tension acts by modulating the sensitivity of the contractile 
proteins of the ductus to calcium.
8.3 PGI2  and the ductus arteriosus.
The current orthodoxy is that PGI2  has little or no role in the control of 
ductus arteriosus smooth muscle (Clyman, 1987; Coceani and Olley, 1988). 
One of the major findings of the work described in this thesis is that PGI2  
almost certainly does have a role in the control of ductus arteriosus smooth 
muscle. The evidence for this is as follows: firstly, PGI2  is the by far main 
product of arachidonic acid in the ductus (see Chapter 1); secondly, the 
maximal dilator effect of PGI2  is greater than PGE2  (see Chapter 6 ); thirdly, 
the sensitivity of the ductus to PGI2  under certain conditions is only an 
order of magnitude less than PGE2  (see Chapter 5) as opposed to three 
orders of magnitude as generally supposed (Clyman et al, 1978c; Coceani 
et al, 1978b); and, forthly, the ductus has a receptor for PGI2  (IP receptor, 
see Chapter 4). It will require the availability of potent selective 
antagonists of the EP4  and IP receptor to clarify more fully the relative 
roles of PGE2  and PGI2  in the regulation of ductal patency.
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Figure 8.2 A model for the effects of oxygen on the ductus arteriosus.
Arrows indicate a stimulatory effect unless there is a minus sign next to the 
point, in which case the effect is inhibitory. The model assumes that the 
contractile EP receptor on the ductus is EP3. This is based on an 
understanding of its pharmacology, but remains to be established (see 
Chapter 7).
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8.4 Vasoconstrictors and the ductus arteriosus.
Recent studies on the ductus have tended to concentrate on the effects of 
oxygen and PGE2, whereas the effect on the ductus of humoral 
vasoconstrictors has been somewhat neglected. However, as outlined in 
Chapter 1, there is evidence that neurally released, locally released and 
circulating vasoconstrictors have effects on the ductus arteriosus. As 
outlined in Chapters 5 and 6 , oxygen tension and PGE2  modulate the 
response of the ductus to noradrenaline-induced contraction, and the two 
factors act synergistically to control profoundly the vessel's response to 
noradrenaline. The effect of PGE2  is not specific to noradrenaline (Chapter
6 ) and it seems likely that fetal oxygen tension and high concentrations of 
PGE2  are responsible for the relative lack of sensitivity of the ductus in 
utero to vasoconstrictors (Friedman et al, 1983). Conversely, the rise in 
oxygen tension and elimination of the dilator effects of PGE2  after birth 
will uncover the response of the vessel to vasoconstrictors.
The control of the activity of pressor nerves and the control of locally 
released and circulating vasoconstrictors in the regulation of patency of 
the ductus arteriosus deserve further attention.
8.5 The role of ductus arteriosus endothelium.
In contrast to many other blood vessels, the endothelium of the ductus 
arteriosus is not thought to have a major role in the regulation of its 
smooth muscle (Fay, 1971; Cobum et al, 1986; Walsh and Mentzer, 
1987). The relatively small maximal effect of the nitric oxide donor, SNP, 
compared with forskolin and prostaglandins (Chapter 6 ), suggests that 
endogenous nitric oxide by the ductus is likely only to have a minor role in 
the control of the ductus. Nevertheless, I have evidence for release of nitric 
oxide by the ductus (data not shown) and the physiological role of this 
should be investigated. In all the experiments described in this thesis, I
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used the endothelium-denuded ductus arteriosus to eliminate any 
complicating factors of the endothelium e.g. changes in endothelial 
function over the course of experiments and the release of nitric oxide 
complicating the effects of contractile agonists.
The role of endothelin in the control of the ductus also needs to be 
addressed, given the conflicting data on its effects (see section 1 .2 .2 ).
8.6 Horizons for the treatment of ductus-dependent circulation.
This work indicated a number of areas for drug development for this 
spectrum of conditions.
Firstly, assuming that the EP receptors on human and rabbit ductus are the 
same, a selective EP4  agonist would be expected to have fewer side effects 
than PGEj and be more potent, as it would not stimulate excitatory EP 
receptors on the ductus. There are several pharmaceutical companies 
working on such drugs at present and there is the very real possibility that 
such a drug may be available in the near future.
Another approach would be the use of a non-EP4  dilator of the ductus. 
The E series prostaglandins were selected for use in ductus-dependent 
circulation in experiments conducted in the presence of indomethacin (see 
Chapter 1). As discussed in Chapter 5, the use of indomethacin will have 
distorted the comparison between E series prostaglandins and other 
vasodilators. The extent of this distortion will depend on the amount of 
endogenous PGE2  to which the ductus is exposed (see Chapter 5). I 
propose that the relative potencies of prostanoid and non-prostanoid 
ductal dilators need to be established in animal models of ductus- 
dependent circulation, in the absence of indomethacin, as this may identify 
other equally effective dilators of the ductus with less severe adverse 
effects than PGE2 .
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Of the various alternative dilators one might consider, I propose that an 
ATP-sensitive potassium channel activator such as cromakalim might be 
the most promising candidate: firstly, cromakalim will specifically inhibit 
the membrane-dependent effect of raised oxygen tension (Nakanishi et 
al, 1983); secondly, the sensitivity of the ductus to cromakalim will be 
potentiated by endogenous PGE2  (see Chapter 5); and, thirdly, the ductus 
is very sensitive to cromakalim compared to other vessels- with the ductus 
pre-contracted with 10pM noradrenaline, lOOnM cromakalim caused 
about 50% relaxation (Figure 5.8), whereas in adult rabbit aorta pre­
contracted with only 0.1 pM noradrenaline, lOOnM cromakalim was sub­
threshold (Bray et al, 1991). This suggests that low concentrations of 
cromakalim may be relatively selective for the ductus.
8.6 Horizons for the treatment of patent ductus arteriosus.
It is proposed that an EP4  receptor antagonist would be more effective and 
less toxic than indomethacin (see Chapter 4). Although this drug would 
not eliminate the effect of PGI2  directly, it may well do so indirectly by 
removing potentiation of the effect of PGI2  by PGE2  (see Chapter 5) 
Furthermore, it would preserve the contractile effects of TP and EP3  
stimulation, which will be eliminated by indomethacin (see Chapter 7). 
Again, such drugs are being developed commercially for other applications 
and there is the real possibility of their being available for evaluation in 
PDA.
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A ppendix.
Tables of 95% confidence intervals of pairwise differences.
Tables of 95% confidence intervals (Cl) of pairwise differences calculated 
using Tukey’s method, following ANOVA where p<0.05.
Values are the 95% Cl of the difference between the mean from the 
column and the mean from the row. Clearly, where the 95% Cl do not 
include zero, a p value of at least less than 0.05 can be inferred.
In each case see text or figure legend for details of units and calculation of 
values.
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Table A.I. Data from Figure 3.1, The effect of stretch on the magnitude
of contraction elicited by indomethacin.
0.1 0.2 0.3 0.6 0.9
0.2 -56.5
24.4
0.3 -83.7
-5.6
-69.0
11.8
0.6 -116.0
-35.2
101.3
■17.8
-71.4
9.5
0.9 -101.7
-23.6
-87.0
- 6.2
-57.1
21.0
-27.5
53.4
1.2 -103.0
-24.9
-88.3
-7.4
-58.3
19.8
-28.7
52.1
-40.3
37.8
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Table A.2 Data from Figure 3.3, The effect of stretch on the maximum 
relaxant response (MRR) to PGE2.
0.1 0.2 0.3 0.6 0.9
0.2 -76.0
9.7
0.3 -95.7
-12.9
-64.0
21.7
0.6 -149.2
-63.5
-117.5
-28.9
-94.9
-9.2
0.9 -142.9
-60.1
- 111.1
-25.4
- 88.6
-5.8
-37.9
47.8
1.2 -145.7
-62.9
-113.9
-28.2
-91.4
- 8 .6
-40.7
45.0
-44.2
38.6
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Table A.3 Data from Figure 3.4, The effect of stretch on the pECS0 to
noradrenaline in l|xM indomethacin and InM PGE2.
0.1 0.2 0.3 0.6 0.9
0.2 -77.5
15.9
0.3 -96.1
-5.8
- 66.8
26.6
0.6 -149.2
-55.8
- 120.0
-23.5
-98.3
-4.9
0.9 -137.9
-47.6
108.6
15.2
-86.9
3.3
-36.9
56.5
1.2 -135.2
-45.0
106.0
12.6
-84.3
6 .0
-34.3
59.1
-42.5
47.8
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Table A.4 Data from Figure 3.4, The effect of stretch on the pEC50 to
noradrenaline in ljxM indomethacin and lOnM PGE2.
0.1 0.2 0.3 0.6 0.9
0.2 -87.7
24.9
0.3 -93.0
15.8
-63.6
49.1
0.6 -147.8
■35.2
-118.3
- 2.0
-109.2
3.4
0.9 -135.6
-26.8
-106.2
6.4
-97.0
11.8
-46.0
66.6
1.2 -133.6
-24.8
-104.1
8.5
-95.0
13.8
-44.0
6 8 .6
-52.4
56.4
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Table A.5 Data from Figure 6.5, Maximum relaxant responses (MRR) 
of vasodilators in lpM indomethacin, IOjiM noradrenaline and 15% 
oxygen.
Adenosine Cicaprost Cromakalim Forskolin PGE2
Cicaprost -96.84
-76.70
Cromakalim -35.95 50.66
-16.14 70.80
Forskolin -107.35 -20.73 -81.31
-85.95 0.97 -59.91
PGE2  -81.27 5.34 -55.23 14.60
-61.13 25.80 -35.09 36.31
SNP -11.43 75.20 14.62 84.49 59.62
9.97 96.90 36.02 107.37 81.33
Table A.6, Data from section 6.2.2, pEC50 to vasodilators in lpM
indomethacin, 10pM noradrenaline and 15% oxygen.
Cromakalim
Forskolin
Cicaprost Cromakalim Forskolin
-0.0868
0.5175
0.0506 -0.1602
0.7018 0.4819
-2.1616
-1.5477
-2.3721 -2.5564
-1.7679 -1.9052
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Table A.7 Data from Figure 6.15, Effect of oxygen on the maximum 
relaxant response (MRR) to PGE2 in lpM indomethacin, lpM  
flubriprofen and absence of cyclo-oxygenase inhibitor (control): MRR 
in 2% oxygen.
Control Indomethacin
Indomethacin -24.029
-6.291
Flubriprofen -27.026
-6.226
- 11.866
8.934
Table A.8 Data from Figure 7.4, Contractile response to U46619,
sulprostone, GR63799X and PGF2(X in lOnM PGE2 at lOOnM.
GR63799X
Sulprostone
- 6.000
10.400
GR63799X
U46619 -13.908 -16.108
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Table A.9 Data from Figure 7.4, Contractile response to U46619, 
sulprostone, GR63799X and PGF2a in lOnM PGE2 at 300nM.
Sulprostone GR63799X
GR63799X -10.57
14.67
U46619 -22.27 -24.32
0.78 -1.27
Abbreviations.
AH13205 (+/-)- trans -2- [4- (1-hyroxyphexyl) phenyl] -5-
oxocylopentaneheptanoic acid 
AH23848B (la(z),2b5a]-7-[5-[[(l,r-biphenyl)-4-yl]methoxy]-
2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic
acid
AH6809 6-isopropoxy-9-oxoxanthine-2-carboxylic acid
ANOVA analysis of variance
ANP atrial natriuretic peptide
ATP adenosine triphosphate
BW245C 5- (6 -carbohexyl) -1- (3- cyclohexyl -3-
hydroxypropylamino) hydantoin, one racemic 
diastereomer
BW8 6 8 C 3-Benzyl -5- (6 - carbohexyl) -1 - (2- cyclohexyl -
2 -hydroxyethylamino) hydantoin 
cAMP cyclic adenosine monophosphate
CCRC concentration contraction response curve
Cl confidence interval
cGMP cyclic guanosine monophosphate
CR concentration ratio
CRRC concentration relaxation response curve
CVO combined ventricular output
DMSO dimethyl sulphoxide
EC5q see section 2.4
EMR equieffective molar ratio
EP 092 (rac 5-endo(6'-caiboxyhex-2'Z-enyl)-6-exo{l"-
[N-(phenylthiocarbamoyl)hydrazono]ethyl}- 
bicyclo[2 .2 .1 ] heptane
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GR63799X [lR-[la(Z),2b(R*), 3a]]-4-(benzoylamino) phenyl
7-[3-hydroxy- 2 (2-hydroxy- 3- 
phenoxypropoxy)- 5- oxocyclopentyl]- 4- 
heptenoate, single enantiomer 
MCR maximum contractile response
MRR maximum relaxant response
NA noradrenaline
NSAID non-steroidal anti-inflammatory drug
PDA patent ductus arteriosus
pEC3 0* see section 6.1.3
pEC5 0  see section 2.4
PG prostaglandin
PSS physiological salt solution
SCI9220 8 -Clorodibenz [b,f] [1,4] oxazepine-10 (11H) -
carboxylic acid, 2 -acetylhydrazide 
SEM standard error of the mean
SNP sodium nitroprusside
Note: less commonly used abbreviations are defined on their first use in 
each chapter; common abbreviations are defined once only, on their 
first use in the thesis (eg PG).
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